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Abstract 
Acute pancreatitis (AP) is a leading cause for hospitalisation and has significant 
quality of life implications for the patient and cost implications for the National 
Health Service. Although most episodes of AP are mild and self-limiting, the 
severe form of the disease is associated with a high mortality. In the absence of 
definitive treatment, management is mainly supportive. There is an urgent need 
to develop more effective biomarkers and drugs to manage AP. Genome-wide 
studies have demonstrated that proteins that bind to heparin (HBPs) form highly 
interconnected networks which are functionally important in health and disease. 
It was hypothesized that this is true in the pancreas and in AP. 
Testing this hypothesis, using mRNA as a proxy for protein, it was shown that 
HBPs constitute an important extracellular sub-proteome within the normal 
pancreas and in major pancreatic diseases that is likely to provide a rich 
repository of potential biomarkers and drug targets. Building upon this work, a 
proteomic analysis of HBPs in normal pancreas (NP) and in caerulein-induced 
mouse AP was undertaken. This has more than doubled the number of HBPs to 
883, with 460 new HBPs identified. These may represent the most interconnected 
set of extracellular proteins and therefore with the greatest regulatory potential. 
Non canonical HBPs such as NDUFS4, NDUFS6, NDUFS7, NDUFS8, NDUFA9, 
NDUFA10, NDUFA9 and NDUFA10 were identified and found to be 
underexpressed in AP as compared to NP. These may have potential moonlighting 
roles, not previously known. By virtue of being extracellular and binding to 
 ii 
heparin, HBPs are accessible and are potential biomarkers and drug targets in AP. 
In addition to identifying existing biomarkers in AP such as pancreatic amylase, a 
number of HBPs with biomarkers potential such as HRG, CD14 and FN1 were 
identified and need further investigation. HBPs such as SERPINC1, VEGFA and 
PIP5K1C need further evaluation in drug development. These along with 
modified heparins, heparin mimetics and matrix therapy in AP provide exciting 
areas for future research. 
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Chapter 1 – INTRODUCTION 
 
1.1 The pancreas 
The pancreas is a retroperitoneal organ located in the upper abdomen. It 
develops from endodermal cells in the embryonic foregut and has important 
exocrine and endocrine functions (Zaret and Grompe, 2008). The exocrine 
pancreas consists of acinar and ductal cells, which are important for nutrient 
digestion (Hegyi and Petersen, 2013). The endocrine pancreas is made up of five 
types of islets cells and regulates glucose homeostasis (Shih et al., 2013). 
 
1.2 Major pancreatic diseases 
The major pancreatic diseases are acute pancreatitis, chronic pancreatitis and 
pancreatic cancer. While the in silico work described in Chapter 2 investigates 
the major pancreatic diseases, the main and further focus of this thesis is acute 
pancreatitis. 
 
1.2.1 Acute pancreatitis 
Acute pancreatitis (AP) is acute inflammation of the pancreas and is mainly 
caused by gallstones and alcohol (Pandol et al., 2007). The diagnosis of acute 
pancreatitis requires the fulfillment of ‘2 out of 3’ of the following criteria: 
clinical (upper abdominal pain), laboratory (serum amylase or lipase >3 times 
the upper limit of normal) and/or imaging (computed tomography, magnetic 
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resonance imaging, ultrasonography) criteria (2013). Its incidence is 
approximately 30 per 100,000 per year in the United Kingdom (Roberts et al., 
2013). Although most episodes are mild and self-limiting, the severe form of the 
disease is associated with mortality of the order of 5% (Schneider et al., 2010, 
Banks and Freeman, 2006). It is the most frequent gastrointestinal cause of 
hospitalisation in the United States and has major socio-economic impacts on a 
health system (Peery et al., 2012). In the absence of specific treatments for AP, 
therapy is mainly supportive (Tenner et al., 2013). 
 
1.2.2 Chronic pancreatitis 
Chronic pancreatitis (CP) is a progressive inflammatory disease associated with 
exocrine and endocrine insufficiency, abdominal pain, significant quality of life 
and nutritional implications. Environmental factors together with numerous 
genetic mutations and polymorphisms predispose to the disease cause CP 
(Gupte and Forsmark, 2014). The pain in CP is multifactorial with inflammatory 
and neuropathic components and its management poses significant challenges. 
Exocrine and endocrine insufficiency occurs as a result of destruction of 
pancreatic tissue. CP is a known risk factor for pancreatic cancer (Lowenfels et 
al., 1993) and its diagnosis often poses a diagnostic dilemma being difficult to 
distinguish it from pancreatic ductal adenocarcinoma (PDAC) clinically and 
radiologically (Johnson and Outwater, 1999).  
 
1.2.3 Pancreatic adenocarcinoma 
Pancreatic ductal adenocarcinoma is the fifth most common cancer worldwide 
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(Parkin, 2008).  Most patients are diagnosed with advanced disease, which rules 
out potentially curative surgery (Vincent et al., 2011). Even after surgery, the 
prognosis remains poor with a 5-year survival of around 10% (Cress et al., 
2006). There is a need to develop more reliable biomarkers and drugs, with a 
view to improving outcome in PDAC. Novel therapeutic strategies targeting the 
pancreatic cancer microenvironment as well as PDAC cells are evolving 
(Costello et al., 2012).  
 
1.3 Pathogenic mechanisms underlying acute pancreatitis 
Pathological processes underlying acute pancreatitis include intra-acinar 
activation of digestive enzymes, the induction of pro-inflammatory mediators, 
such as the transcription factor nuclear factor kappa-B (NF-kB), resulting in 
inflammatory cell infiltration in the pancreas, systemic inflammatory response 
and acinar cell death through apoptosis and necrosis (Gukovskaya and Pandol, 
2004, Pandol et al., 2007, Saluja et al., 2007). Recent advances have provided 
new insights into the pathogenic mechanisms underlying acute pancreatitis 
(Criddle et al., 2007, Booth et al., 2011, Voronina et al., 2014, Gukovsky et al., 
2011) and have primarily focussed on signalling pathways involved in these 
processes (Gukovsky et al., 2011, Sah et al., 2012).  
 
1.3.1 Abnormal Calcium signalling 
Disruption of normal Ca2+ signaling has been suggested as a trigger for acute 
pancreatitis over a decade ago. Major precipitants of acute pancreatitis such as 
bile salts and non-oxidative metabolites of ethanol generate toxic elevations of 
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Ca2+ that result in cellular necrosis. A sustained rise in cytosolic Ca2+ is 
pathologic and results in a sustained increase in mitochondrial Ca2+. This in turn 
causes a decreased ATP production, which impedes the clearance of Ca2+ from 
the cell, resulting in trypsinogen activation, vacuolisation, and necrosis (Booth 
et al., 2011). Aberrant Ca2+ influx via store operated Ca2+ channels (SOCs) has 
been implicated in many diseases including AP (Lee et al., 2010). The entry of 
Ca2+ through SOCs involves the interaction of the stromal interaction molecule 
(STIM) and Orai at the ER-PM (endoplasmic reticulum-plasma membrane) 
junction and phosphoinositides contribute to the accumulation of STIM1 at this 
location (Walsh et al., 2010). 
 
1.3.2 Mitochondrial dysfunction 
ER–mitochondria membrane microdomains meet the Ca2+ demand for ATP 
generation and oxidative phosphorylation in the mitochondria, regulate 
apoptosis and mediate ATP and redox signaling from mitochondria to 
endoplasmic reticulum (Cardenas et al., 2010, Pinton et al., 2008). The ER–
mitochondria interactions may be crucial in containing/propagating pathologic 
Ca2+. Mitochondrial permeability transition pore (PTP) opening and loss of 
mitochondrial membrane potential are recognized events during pancreatitis, 
leading to release of mitochondrial contents into the cytosol, ATP depletion and 
oxidative stress (Mukherjee et al., 2008). 
 
1.3.3 Endoplasmic reticulum stress response 
Endoplasmic reticulum (ER) stress and oxidative stress are known to occur 
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early in pancreatitis (Sah and Saluja, 2011). Mitochondrial dysfunction results 
in oxidative stress, which in turn results in the generation of reactive oxygen 
species (ROS). This modulates ATP generation, which when inhibited results in 
acinar necrosis (Section 1.3.1, 1.3.2) (Booth et al., 2011). Neutrophil generated 
ROS and mitochondrial ROS result in the activation of inflammatory pathways in 
acute pancreatitis. 
 
1.3.4 Impaired autophagy due to lysosomal dysfunction 
Mitochondrial dysfunction and ER stress induce autophagy (Gukovsky et al., 
2012, Lugea et al., 2011). Autophagy protects the acinar cell from the 
deleterious effect of released activated enzymes in acute pancreatitis (Grasso et 
al., 2011).  Impaired lysosomal digestion of autophagic contents in turn results 
in impaired autophagy and so a loss of protection of the cell by this mechanism 
(Gukovsky et al., 2012). 
 
1.3.5 Impaired cellular trafficking 
As a result of a loss of acinar cellular and cytoskeletal reorganization, apical 
secretion is impaired in acute pancreatitis (Gorelick and Thrower, 2009). 
Consequently, basolateral exocytosis occurs, which exposes the basolateral 
soluble N-ethylmaleimide-sensitive factor attachment receptor (SNARE) 
complex. This in turn results in zymogen granules attaching to the basolateral 
membrane causing subsequent acinar injury (Gaisano and Gorelick, 2009). 
VAMP8 (vesicle-associated membrane protein 8) has been shown to be the 
SNARE that mediates basolateral exocytosis in a mouse model of acute 
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pancreatitis (Cosen-Binker et al., 2008). 
 
1.4 Experimental murine models of acute pancreatitis 
 Various animal models have been created over the years with a view to 
investigate the pathogenic mechanisms underlying acute pancreatitis. While 
many species have been used for these models, most investigators use rodent 
models, either mice or rats, as they are better standardised, less expensive to 
maintain and, in the case of mice, can be easily manipulated genetically for 
studies. 
 
1.4.1 Secretagogue hyperstimulation model 
This has been the most widely used murine model of acute pancreatitis (Lerch 
and Gorelick, 2013) and supramaximal cholinergic stimulation of the pancreas 
with  caerulein, which is an ortholog of the intestinal hormone cholecystokinin, 
is physiologically relevant. The most widely used protocol for the induction of 
acute pancreatitis in mice today involves 7 intraperitoneal injections, 1 hour 
apart, of 50 µg/kg body weight of synthetic caerulein. The advantages of the 
secretagogue model of acute pancreatitis include its lack of requirement for 
surgery or complicated manipulations and its suitability for studying the whole 
spectrum of the disease from mild to severe acute pancreatitis (Lerch and 
Gorelick, 2013). 
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1.4.2 Duct obstruction and bile acid infusion model 
This model seeks to mimic gall stone pancreatitis and is based on the hypothesis 
that if a gallstone at the papilla obstructs the common channel that connects the 
common bile duct to the pancreatic duct, bile could enter the pancreas and thus 
would induce pancreatitis. Common channel ligation models of acute 
pancreatitis are relevant to human disease (Kamisawa et al., 2009, Kamisawa et 
al., 2007). While duct ligation in opossum results in pancreatic necrosis (Lerch 
et al., 1993), rodent models are poorly suited for investigations, as they lack 
severity (Samuel et al., 1994) . Infusion of bile acids into the pancreatic duct 
results in acute pancreatitis of varying severity depending on the concentration 
of the infused bile acid (Perides et al., 2010). 
 
1.4.3 Basic amino acid induced model 
This non-invasive model induces severe acute pancreatitis in rats by the 
intraperitoneal injection of high concentrations of L-arginine (Mizunuma et al., 
1984). The advantage of this model is its severity, while a major disadvantage is 
that its mechanistic relevance to human acute pancreatitis is uncertain (Lerch 
and Gorelick, 2013). 
 
1.4.4 Diet induced model 
In this model, mice are fed a choline-deficient diet enriched with ethionine, a 
derivative of methionine and develop severe necrotizing pancreatitis (Lombardi 
et al., 1975), with up to 100% dying within 5 days. This model shares many 
common features with the secretagogue hyperstimulation model, though with a 
 8 
higher severity of the disease (Gilliland and Steer, 1980). 
 
1.5 The need for more accurate prognostic biomarkers and for drug 
development in acute pancreatitis 
Most patients with acute pancreatitis have a mild course, which settles within 3-
5 days (Raraty et al., 2004). However, about 20 percent of patients have a severe 
course, which is associated with a high mortality (Whitcomb, 2006). These 
patients require specialist intervention and multi-organ support (Raraty et al., 
2004) and also have major cost implications for a health system (Peery et al., 
2012). The early identification of patients with the severe form of the disease is 
key to effective management and allocation of resources (Raraty et al., 2004, 
Gomatos et al., 2014). A number of clinical features and laboratory markers 
have been used over the years, alone or in combination with scoring systems, to 
determine prognosis. However, no single laboratory marker or score can 
accurately predict the outcome in acute pancreatitis (Mounzer et al., 2012).  
 
1.5.1 Scoring Systems in acute pancreatitis 
The Ranson score is the earliest multifactorial scoring system to be proposed in 
the management of acute pancreatitis and is based on eleven factors calculated 
at admission and at 48 hours (Ranson et al., 1974).  This system is not accurate 
until 48 hours into the course of the disease and the sensitivity of the score 
decreases with incomplete data collection (Ranson et al., 1974). The modified 
Glasgow score includes eight factors, namely, serum albumin, blood urea 
nitrogen, calcium, white cell count, lactate dehydrogenase, age and glucose  
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Scoring 
System 
Time Parameters Sensitivity 
(%) 
Specificity 
(%) 
Ranson 
Score 
At admission 
and at 48 
hours 
 At admission: 
Age (>55 years), WBC 
(>16,000/mL), glucose 
(>200 mg/dL), LDH 
(>350 IU/mL), AST 
(>250 IU/mL)  
At 48 hours: haematocrit 
decrease (>10%), BUN 
increase (>5 mg/dL), 
calcium (<8 mg/dL), 
PaO2 <60 mm of Hg, base 
deficit >4 mEq/L, fluid 
sequestration (>6L) 
46 80 
Modified 
Glasgow 
Score 
At admission 
and at 48 
hours 
Age (>55 years), WBC 
(>15,000/mL, glucose 
(>180 mg/dL), BUN (>45 
mg/dL), PaO2 (<60 mm 
Hg), calcium (<8 g/dL), 
albumin (<3.2 g/dL), 
LDH (>600 IU/L) 
65 82 
APACHE II At admission 
and at 48 
hors 
At admission and at 48 
hours: 
Temperature, MAP, 
heart rate, respiratory 
rate, PaO2, arterial pH, 
HCO3, sodium, 
potassium, creatinine, 
haematocrit, WBC, 
Glasgow Coma Score, 
age, chronic health 
points 
97 44 
BISAP At admission 
and at 48 
hours 
At admission and at 48 
hours: 
BUN (>25 mg/dL, 
impaired mental status 
(Glasgow Coma Score 
<15), SIRS (>/= 2), age 
(>60 years), pleural 
effusion 
62 76 
 
 
Table 1.1: Comparing the clinical scoring systems in acute pancreatitis. WBC White 
blood count, LDH Lactate dehydrogenase, AST Aspartate aminotransferase, BUN 
Blood urea nitrogen, MAP Mean arterial pressure, SIRS Systemic Inflammatory 
Response Syndrome 
The Glasgow score has been shown to be the best predictor of organ failure at 
admission. 
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levels. The APACHE (Acute Physiology and Chronic Health Evaluation) II system, 
which was initially developed for patients admitted to critical care units, was 
similar in predictive accuracy as the Ranson and Glasgow scores (Larvin and 
McMahon, 1989). Also, the Glasgow score requires the collection of a large 
number of parameters that can be tedious (Mounzer et al., 2012). The ‘Bedside 
Index of severity in acute pancreatitis’ (BISAP) scoring system was developed 
using data collected within the first 24 hours of hospitalisation for acute 
pancreatitis and includes five parameters: blood urea nitrogen levels of greater 
or equal to 25 mg/dL, impaired Glasgow coma scale of <15, a systemic 
inflammatory response syndrome (SIRS) score of greater or equal to 2 (heart 
rate >90 beats/min, core temperature <36 or >38ºC, white cell count <4 or >12 
109/L, respirations >20/min or PaCO2 <32 mmHg), age greater than 60 years 
and pleural effusion (Wu et al., 2008).  The Glasgow score was found to be the 
best classifier for predicting persistent organ failure at admission in a study 
(Table 1.5.1) comparing the Ranson’s, Glasgow, APACHE II and BISAP scoring 
systems (Mounzer et al., 2012). The Atlanta Symposium in 1992 attempted to 
establish a global consensus on a classification system for acute pancreatitis 
(Bradley, 1993). This was recently revised in keeping with advances in the 
understanding of the pathophysiology of acute pancreatitis, as well as the 
advances in diagnostics (Banks et al., 2013).  This revised system uses the 
modified Marshall score for organ dysfunction (Marshall et al., 1995). A 
determinant-based classification of acute pancreatitis, based on local and 
systemic determinants of severity of the disease, has also been recently 
proposed (Dellinger et al., 2012). This classification system uses the sepsis-
related organ failure assessment scoring system for organ dysfunction (Vincent 
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et al., 1996). A consensus on the same has yet to be reached (Talukdar and Rau, 
2014). A study to comparing it with the Revised Atlanta Classification showed 
that the Determinant Classification predicted the length of hospital stay better, 
whereas the Revised Atlanta Classification predicted interventions in acute 
pancreatitis better (Acevedo-Piedra et al., 2014). 
 
1.5.2 Molecular markers of acute pancreatitis 
1.5.2.1 Biomarker definitions 
A biomarker is defined as “a characteristic that is objectively measured and 
evaluated as an indicator of normal biological or pathogenic processes, or 
pharmacologic responses to therapeutic intervention” 
(Biomarkers_Definitions_Working_Group, 2001). Biomarkers may be classified 
as prognostic, predictive or pharmacodynamics and ideal biomarkers are highly 
sensitive and specific (Amur et al., 2008). Prognostic biomarkers indicate the 
likely course of a disease irrespective of treatment, whereas predictive markers 
suggest the population of responders to a particular treatment (Drucker and 
Krapfenbauer, 2013). Pharmacodynamic biomarkers indicate the therapeutic 
and adverse outcome of interactions between a drug and its targets. Clinical 
biomarkers may be stratification markers, efficacy markers, toxicity markers or 
surrogate endpoint markers (Lassere et al., 2007). Guidelines such as 
“STAndards for Reporting of Diagnostic accuracy (STARD)” have been 
introduced to help in the description of key elements of biomarker study design 
and execution (Bossuyt et al., 2003). The STARD initiative included key 
elements of biomarker study design, execution, patient recruitment, diagnostic 
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tests and statistical analyses to guide researchers. 
 
1.5.2.2 Biomarkers in acute pancreatitis 
C-reactive protein (CRP) is a non-specific marker, which is probably the most 
widely used predictor of severity in AP (Schutte and Malfertheiner, 2008). 
Serum amyloid A is an acute phase reactant that reaches significantly high levels 
in patients with pancreatic necrosis and is more accurate than CRP in predicting 
severity (Pezzilli et al., 2000). Procalcitonin is the biologically inactive form of 
calcitonin and is an acute phase reactant is useful in predicting severity as well 
as infected pancreatic necrosis and sepsis (Rau et al., 1997). Cytokines are 
inflammatory mediators and inducers of synthesis of acute phase reactants. 
Interleukin-6 significantly increases in severe acute pancreatitis, however, its 
levels decrease rapidly during the course of the disease and it is unreliable in 
predicting mortality (Ikei et al., 1998). Interleukin-8, on the other hand, may 
predict multi-organ failure and maybe be used as a marker of progression 
(Mayer et al., 2000, Dugernier et al., 2003). Trypsinogen is cleaved by trypsin 
itself or by duodenal enterokinase into its active form trypsin and trypsinogen 
activation peptide (TAP). The kidneys excrete TAP in urine. Urinary TAP has 
been shown to be superior to CRP at 24 hours after admission in predicting the 
severity of acute pancreatitis (Johnson et al., 2004). However, as its levels 
decrease rapidly it cannot be used to monitor disease progression. 
Polymorphonuclear (PMN) elastase is released by PMN granulocytes and is a 
good predictor of severity of acute pancreatitis, peaking 24 hours after disease 
onset (Dominguez-Munoz et al., 1991). Studies show that a combination of 
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markers, such as interleukin-10 and serum calcium (Mentula et al., 2005), PMN 
elastase and CRP (Viedma et al., 1994), CRP and urinary TAP (Lempinen et al., 
2001), hold promise. 
 
1.5.3 Drug development in acute pancreatitis 
Various therapeutic agents have been investigated to treat acute pancreatitis. 
Inhibition of pancreatic secretion used to be thought to be protective in acute 
pancreatitis.  However, while several randomized controlled trials with anti-
pancreatic secretion therapy using somatostatin have failed to show any 
significant clinical benefit in acute pancreatitis (Choi et al., 1989, D'Amico et al., 
1990, Luengo et al., 1994, Gjorup et al., 1992), a meta-analysis of 7 studies 
showed an overall mortality advantage benefit with somatostatin in the severe 
form of the disease (Andriulli et al., 1998). Similarly, the clinical benefit of the 
somatostatin analogue, octreotide, is yet to be demonstrated convincingly (Uhl 
et al., 1999, Heinrich et al., 2006). Both somatostatin and octreotide need 
further investigation with respect to the dosage, timing of administration, the 
target population and their cost-effectiveness (Li et al., 2011). There is no 
concrete evidence to support the use of antiprotease therapy in treating acute 
pancreatitis (Kitagawa and Hayakawa, 2007). While the use of the protease 
inhibitor gabexate mesilate has shown no clinical benefit in acute pancreatitis 
(Valderrama et al., 1992, Buchler et al., 1993), continuous regional arterial 
infusion with Nafomostat in combination with antibiotics warrants further 
investigation (Imaizumi et al., 2004, Piascik et al., 2010). Lexipafant, a platelet 
activating factor receptor antagonist and anti-inflammatory drug, failed to show 
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a reduction in multiple organ dysfunction syndrome (MODS) and mortality in 
patients with severe acute pancreatitis (SAP) compared to placebo treatment in 
a double-blinded randomised clinical trial (RCT) (Johnson et al., 2001). The 
prophylactic use of antibiotics has not been shown to significantly reduce 
mortality, or the requirement for surgical intervention (Hackert and Werner, 
2011), while antioxidant therapy has not shown to have a protective effect, but 
on the contrary seemed to augment the severity of acute pancreatitis 
(Siriwardena et al., 2007). In a large multicentre RCT antibiotic prophylaxis in 
combination with probiotic strains did not reduce the risk of infectious 
complications severe acute pancreatitis and was associated with an increased 
risk of mortality (Besselink et al., 2008). Despite an increased understanding of 
the pathophysiology of acute pancreatitis in the last two decades, a specific 
therapy for AP is lacking and treatment remains largely supportive (Tenner et 
al., 2013).  
 
1.6 Systems biology and systems medicine 
 ‘Reductionism’, in principle, is useful in investigating diseases, particularly in 
conditions where one or a few components are responsible for the overall 
outcome. It is useful and effective when an isolatable problem exists and where 
a quick and effective solution is available e.g. diseases such as acute appendicitis 
and urinary tract infections. However, this approach is less effective in 
investigating systems in which interactions between components dominate the 
systems themselves, thereby influencing behaviour and outcomes. This is the 
case in complex organs such as the pancreas and complex diseases such as acute 
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pancreatitis (Ahn et al., 2006). This has had an impact on drug design and the 
number of successful novel, single-target drugs developed over the past decades 
(Butcher, 2005). Previously, the reductionist approach to drug development has 
resulted in many successful single-target drugs. Single target drugs, however, 
are less able to combat the complex pathologies of inflammatory diseases and 
cancer, which are regulated by multiple and often partly redundant molecular 
inputs (Leung et al., 2012). Hence, single target drugs are sometimes used in 
combination which each other. 
The last decade has seen enormous advances in the ‘omics’ technologies and the 
explosion of public databases for molecular interaction data (Kwoh and Ng, 
2007). These data pose challenges of representation and analysis. This period 
has also seen the emergence of the concept of ‘Systems Biology’. Systems 
biology adopts a holistic approach integrating experimental and computational 
research to investigate biological systems and this is particularly useful in 
understanding complex diseases such as acute pancreatitis, where a number of 
biological processes and pathways are involved. Spatial and temporal variability 
provide useful information regarding a system and are particularly important in 
a systems biology approach (Ahn et al., 2006). The analyses of the genetic 
profiles of various complex diseases such as lymphoma (Rosenwald et al., 
2002), breast cancer (Zhang et al., 2003) and lung cancer (Au et al., 2004) have 
shown us that seemingly single phenotypes can have multiple etiologic and 
pathologic processes underlying them, which in turn can impact prognosis and 
response to therapeutic strategies (McCarthy et al., 2013, Gustafsson et al., 
2014, Hagg et al., 2009). The ‘MammaPrint’ is a commercially available 
diagnostic biomarker product to stratify breast cancer based on gene 
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expression profiling (Kittaneh et al., 2013). A disease module-based approach to 
drug discovery in rheumatoid arthritis (Okada et al., 2014) and a combinatorial 
approach integrating mathematical models and high-throughput data have been 
used to generate disease-specific models for the identification of drug targets in 
tuberculosis (Rienksma et al., 2014). ‘Systems medicine’ uses spatial and 
temporal information with a view to achieving a holistic approach to an 
individual. In future, optimal treatment of diseases is likely to be based on 
‘personalised medicine’ (Ahn et al., 2006) as evidenced by the optimisation of 
warfarin-based anticoagulant therapy using genotyping (Pirmohamed et al., 
2013). Adopting a ‘Systems’ approach is likely to increase the possibility of 
developing more effective drugs with an improved safety profile, as well as 
developing multi-target drugs (Schrattenholz et al., 2010).  
 
1.7 The extracellular matrix 
The extracellular matrix (ECM) is a three-dimensional component of the 
microenvironment containing cells and bioactive molecules and lies between 
the plasma membranes of cells. The ECM is a dynamic space and plays an 
important role in homeostasis. It acts as a reservoir for bioactive molecules such 
as growth factors, cytokines and so on. Its biophysical and biochemical 
properties vary in health and disease (Hynes, 2009). There is an abnormal 
accumulation of ECM in inflammation and cancer that increases the stiffness of 
the tissue and leads to increased tissue hypoxia (Kong and Mooney, 2007). The 
altered ECM may also affect the transmission of bioactive molecules in the 
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microenvironment and may thereby influence cell signalling (Duchesne et al., 
2012).  
Extracellular proteins, including those of the ECM, are suggested to have played 
a central role in vertebrate evolution (Huxley-Jones et al., 2009). A genome-
wide analysis by Vogel and Chothia has shown that these proteins expanded 
significantly with a concomitant expansion in their contribution to function as 
the biological complexity of organisms increased (Vogel and Chothia, 2006).  
Subsequently, Ori et al. demonstrated that within the extracellular proteins 
those that bind to heparin, form an important integrated functional network 
(Ori et al., 2011). Thus, the ECM could constitute an important repository for 
biomarker discovery and drug development. In AP, the regenerative response to 
the damaged pancreas is determined by a balance between the synthesis and 
degradation of ECM. Various constituents of the ECM play important roles in 
maintaining this balance. Transforming growth factor beta 1 (TGF1) promotes 
angiogenesis, stimulating the production of fibronectin and collagen (Border 
and Noble, 1994, Nakamura et al., 2007). It also reduces the synthesis of 
proteases and increases the production of protease inhibitors (Sporn and 
Roberts, 1992)  and can induce fibrosis. Matrix metalloproteinase-2 (MMP-2) 
has been shown to promote healing following an attack of AP (Kihara et al., 
2001). 
 
1.8 Heparan sulfate and heparin 
1.8.1 Structure 
Heparan sulfate (HS) is a linear sulfated polysaccharide expressed by most 
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animal cells (Xu and Esko, 2014). Structurally, HS contains a characteristic 
disaccharide-repeating unit (Fig. 1.1) and belongs to the family of 
glycosaminoglycans (GAG). The basic building block consists of β1–4-linked D-
glucuronic acid (GlcA) and α1–4-linked N-acetyl-D-glucosamine (GlcNAc). HS 
chains have a molecular weight between 20 to 100 kDa and typically consist of 
50 to 250 disaccharide units of D-glucuronic acid and N-acetyl-D-glucosamine.  
Figure 1.1 The disaccharide units of heparan sulfate and heparin (A) the GlycA β 1-
4 GlcNAc unit, which is the initial product of polymerisation.  (B) N-
deacetylation/N-sulfation of the glucosamine marks the disaccharide unit for further 
modification, including epimerisation of GlcA to IdoA and O-sulfation at C2 of the 
IdoA, C6 of GlcNS.  The trisulfated disaccharide makes up ~75% of heparin, 
whereas it is less frequent in the S-domains of heparan sulfate, which are less 
sulfated. 
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The formation of HS chains is initiated by the formation of a tetrasaccharide 
linkage region, synthesized by stepwise addition of xylose, followed by two 
galactose units and a glucuronic acid residue to a serine residue in the core 
protein. The first N-acetyl-glucosamine residue is then transferred to the 
linkage region, followed by extensive addition of glucuronic acid and N-acetyl-
glucosamine units in alternating sequence. The nascent GAG chain is modified 
by sulfotransferases and an epimerase. First, some of the N-acetylglucosamine 
residues are N-deacetylated and N-sulphated by a dual-activity N-deacetylase/ 
N-sulphotransferase enzyme, using 3′-phosphoadenosine-5′-phosphosulphate 
as sulphate donor. The partially N-sulfated polysaccharide is then acted upon by 
glucuronyl C5-epimerase. This converts glucuronic into iduronic acid residues. 
The modification process is completed through 6-O- and 3-O-sulfation of 
glucosamine units.  At each step only a fraction of substrates are modified which 
is responsible for considerable sequence diversity in HS chains. 
These modification reactions all depend on the presence of N-sulfated 
glucosamine; that is they occur on the N-sulfated disaccharide unit or on the 
adjacent unit.  There are four N-deacetylase/ N-sulfotransferase enzymes 
encoded in the human genome, but they all have in common the property of 
modifying blocks of N-sulfated glucosamine, with N-deacetylase/ N-
sulfotransferase modifying very long blocks and the others leaving substantial 
tracts of unmodified disaccharides.  The consequence is that heparan sulfate has 
a domain structure.  From the tetrasaccharide linker there is an unmodified 
domain, termed NA (N-acetylated).  This is followed by a transition domain, 
where between one in two and one in three disaccharides is N-sulfated (termed 
NAS domain) and an S-domain (sulfated), where each glucosamine is N-sulfated. 
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The S-domain is flanked on the non-reducing end by another NAS domain, 
which is followed by an NA domain and so on.  The S domains are the most 
heavily sulfated. 
 After secretion to the cell exterior, the HS chains may be edited through SULF-
catalysed 6-O-desulphation. HS chains are structurally dynamic and change with 
time and cellular physiology (Lindahl and Lindahl, 1997, Feyzi et al., 1998, 
Jayson et al., 1998). Characteristic differences in the structure of HS have been 
demonstrated with certain diseases, age and transition to malignancy (Lindahl 
and Lindahl, 1997, Lindahl et al., 1995). The factors that control the biosynthetic 
machinery in the Golgi and so determine the size and composition of HS chains 
in different cells and at different times are yet to be unraveled.  
Heparin is used as an experimental proxy for cellular heparan sulfate, because it 
resembles a very large S-domain, but is somewhat more sulfated even than 
these, due to its synthesis being uniquely driven by N-deacetylase/ N-
sulphotransferase-1. Heparin is the largest drug in production worldwide (Xu 
and Esko, 2014).   
 
1.8.2 Heparan sulfate proteoglycans 
Heparan sulfate proteoglycans (HSPGs) consist of a core protein with one or 
more covalently linked HS chains. There are 17 HSPGs that have been identified, 
which reside either in the plasma membrane or in the extracellular matrix. It is 
not yet clear whether the core protein influences the structure of HS (Xu and 
Esko, 2014).  
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1.8.3 Heparin-binding proteins 
Proteins that bind to heparin at physiologically relevant ionic strength and pH, 
are called heparin-binding proteins (HBPs). Approximately 435 HBPs are 
known (Ori et al., 2011). HBPs belong to a wide range of functional categories 
ranging from cytokines and chemokines to enzymes and matrix proteins. They 
can bind to more than one sequence in HS and may also bind to other 
glycosaminoglycans (GAGs) such as chondroitin sulfate, dermatan sulfate and 
hyaluronic acid (Xu et al., 2012).  
 
1.8.4 Interaction between HS and HBPs 
1.8.4.1 Molecular basis of binding 
 
At the molecular level, ionic bonding is an important feature of the interaction 
of HBPs with HS and other sulfated glycosaminoglycans. Thus, the negatively 
charged sulfate and carboxyl groups of HS interact with positively charged 
lysine and arginine residues in the heparin-binding proteins (HBPs). Polar 
residues and the amide of the peptide backbone also interact with these charged 
groups on the sugar, as well as participating in hydrogen bonds with the various 
oxygen and hydrogen atoms of HS (Ori et al., 2008). Although the kinetics of 
HBP binding to HS are dominated by the ionic interactions, energetically these 
are not necessarily dominant, evidenced by the lack of correlation between the 
concentration of electrolytes required to abrogate binding and binding affinity 
(Ori et al., 2008, Xu et al., 2012). One reason is that HBP binding to HS often 
causes substantial conformational change in the protein, as seem, for example, 
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by differential scanning fluorimetry and circular dichroism (Uniewicz et al., 
2010, Xu et al., 2012, Uniewicz et al., 2014, Xu et al., 2013) and classically seem 
in the interaction of Antithrombin-III (AT-III) with anti coagulant heparin 
(Evans et al., 1992, Huntington, 2003). 
The specificity and selectivity of the interactions between HBPs and HS is the 
matter of some debate.  The high specificity of AT-III for a pentasaccharide 
sequence with a 3-O sulfate (the basis of heparin's anticoagulant activity) has 
led to the argument that many HBPs will possess a similar "high affinity" site in 
HS, but the sequence complexity of HS means that these have yet to be 
discovered. At the other extreme is the view that the interaction of HBPs is 
simply due to charge and that there is little selectivity or specificity, as found 
with thrombin, and so the interaction of AT-III is an exception. A more 
pragmatic view is that all HBPs can bind a range of structures, even AT-III, with 
varying affinity and it is possible to generate on, for example, an unrelated plant 
polysaccharide, functional, high affinity binding structures for HBPs (Rudd et al., 
2010). Analysis of a group of evolutionarily related HBPs, the fibroblast growth 
factors (FGFs), has suggested that there is indeed specificity in the structures 
recognised by FGFs in HS, and though this is not absolute (so 1;1), it has arisen 
through natural selection and so likely to be of functional significance (Xu et al., 
2012).  
 
1.8.4.2 Functions of interaction with HS  
The binding of HBPs to HS has many functions, which include protein 
stabilisation, scaffolding two proteins so they may interact more effectively, 
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including formation of ligand-receptor complexes, and localisation and 
transport.  
The conformational change often observed upon HS binding increases protein 
stability (the basis of the above differential scanning fluorimetry assay) 
(Uniewicz et al., 2010, Xu et al., 2012). This improves the life span of some HBPs 
by preventing their degradation by proteases in the extracellular environment 
and is likely also important in the highly reactive environments seen for 
example, in inflammation.  
The scaffold provided by HS can also act as a catalyst of encounters to promote 
more effective interactions of HBPs with one another. The combination of 
conformational change and catalysis of encounters is illustrated by the 
consequences of the binding of AT-III to heparin. This induces a structural 
rearrangement in AT-III that results in the expulsion of a loop containing a 
protease-reactive site; since the AT-III targets also bind heparin, the degrees of 
freedom of the collision between AT-III and its targets are reduced.  Together, 
these two effects dramatically increases the inhibitor activity of AT-III against 
coagulation factors thrombin by 9000-fold and Factor X by 17000-fold, 
respectively (Whisstock et al., 2000). Different crystal structures of AT-III 
complexed with different saccharides and in a ternary complex with its 
substrates have been demonstrated to elucidate this mechanism (Imberty et al., 
2007, Whisstock et al., 2000). HS may also be considered an allosteric 
modulator of HBPs, as evidenced by the crystallization studies of HS-dependent 
conformational change of AT-III (Langdown et al., 2009).  
A further example of a scaffolding function is provided by the HS-dependent 
ligands (growth factors, morphogens, chemokines and cytokines).  To generate 
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signals through their cognate membrane receptor, these have to form a ternary 
complex that also includes HS.  The FGFs provide the paradigm for what is 
termed the “co-receptor” function of HS. Thus, the stimulation of biological 
processes such as cell proliferation requires the formation of a ternary complex 
of FGF, FGF receptor (FGFR) and HS (Yayon et al., 1991, Rapraeger et al., 1991). 
In this complex, HS binds both the FGF ligand and the FGF receptor 
(Schlessinger et al., 2000).  In the absence of HS, though the FGF ligand still 
binds its cognate receptor, signalling kinetics are very different and in this 
instance, cell proliferation is not stimulated (Zhu et al., 2010) 
HS will act as a tether, and so immobilise HBPs and concentrating them at a 
specific location in the extracellular space, which is likely important for 
regulating and directing the activity of HBPs that are enzymes. Such binding is 
also critical for the formation of gradients of HBPs that are signalling molecules, 
so cytokines, chemokines, growth factors and morphogens. For example, recent 
work has demonstrated that the transport of FGF-2 in pericellular matrix is 
controlled by its binding to HS (Duchesne et al., 2012). Indeed, disruption of the 
interactions of such HBPs with HS has been found to have a profound effect on 
cell communication in development, homeostasis and disease, in part due to the 
disruption of the transport of these effectors from source to target cell. 
 
1.8.5 Roles of HS, HSPGs and HBPs in health and disease 
HS and HSPGs play critical roles in embryogenesis and the development of 
various organs (Maeda et al., 2011, Miner, 2011, Thompson et al., 2010). The 
absence of HS is not compatible with life (Lin et al., 2000, Habuchi et al., 2007). 
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The targeted deletion of genes involved in the biosynthesis of HS results in 
embryonic and perinatal lethality in mice. The homozygous deletion of Ext1 or 
Ext2 genes, which encode HS polymerase enzymes, causes failure of 
gastrulation, while the heterozygous condition (Ext2) is associated with the 
development of exostoses and multiple cartilage deformities (Wang et al., 2005, 
Fuster et al., 2007). Loss of glucuronyl C5-epimerase is lethal for neonates and 
its targeted disruption caused synthesis of HS chains devoid of IdoA with a 
resultant loss of kidneys, poorly inflated, immature lungs and skeletal 
abnormalities (Li et al., 2003). The unique structure of HS affords it the ability to 
bind to variety of proteins thereby influencing their activity (Ori et al., 2008). 
HSPGs create preferential diffusive paths for their ligands by altering the shape 
of morphogen gradient residues thereby influencing diffusivity through the ECM 
(Lander, 2007), as evidenced directly in fibroblast pericellular matrix 
(Duchesne et al., 2012). The elucidation of the mechanism of activation of AT-III 
was the first example of how heparin influences protein function by inducing 
conformational change (Langdown et al., 2009). Many HBPs are important 
signalling molecules in the microenvironment and regulate fundamental 
biological processes such as cell adhesion, differentiation, proliferation and 
migration, organogenesis, lipid metabolism, inflammation and cancer (Ori et al., 
2011). On a genome-wide basis, HBPs have been shown collectively to play a 
pivotal role in driving biological complexity and influence fundamental 
processes underlying complex diseases (Ori et al., 2011).  Thus, the 
identification of HBPs and the understanding of HS-HBP interactions would be 
useful in developing heparin-based and HBP targeted therapeutic interventions.  
This has already been initiated in the field of regenerative medicine, in the 
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treatment of non-healing ulcers (Barbier-Chassefiere et al., 2009).  
 
1.8.6 Therapeutic potential of HS-HBP interactions 
Heparin is the largest drug by weight in production today and has been in 
clinical use for decades (Xu and Esko, 2014). There is great potential for drug 
development based on HS-HBP interactions in cancer and inflammation 
(Coombe and Kett, 2005). The phosphosulfomannan PI-88, which is based on a 
heparin-like structure, was designed with a view to targeting a number of HBPs 
in cancer and was tested as such in clinical trials in cancer patients (Yu et al., 
2002). More recently, its heparanase inhibitory activity, which will be anti-
metastatic and anti-angiogenic, has provided the basis for Phase III trials in 
post-resection hepatocellular carcinoma (Kudchadkar et al., 2008, Liu et al., 
2009).  Some drugs have been developed to specifically target single HBPs. A 
drug that has been developed using this approach is Fondaparinux, which is the 
first synthetic heparin (Bauer, 2003). This drug does not bind to platelet factor 
4 and does not cross react with antibodies generated as a result of heparin-
induced thrombocytopenia, thereby eliminating many of the side effects of 
heparin therapy (115). SST0001 is a modified heparin derivative that has 
shown anti-angiogenic activity in the preclinical setting and has recently 
entered Phase I clinical trials in multiple myeloma (Ramani et al., 2013). PG545 
is a synthetic HS mimetic has been shown to have antitumour and 
antimetastatic properties in a breast carcinoma model (Hammond et al., 2012). 
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1.9 Proteomics as a tool to investigate the extracellular matrix in acute 
pancreatitis 
Global strategies such as proteomics, along with genomics and transcriptomics 
present a novel methodological approach to investigating disease and have been 
used in AP (Anderson and Anderson, 1998, Pociot and Karlsen, 2002, Buchholz 
et al., 2001). However, mRNA levels often do not correlate to those of the 
corresponding proteins (Schwanhausser et al., 2011). Extensive protein 
analyses are, therefore, necessary to gain comprehensive information of cellular 
transactions and correlate them with disease (Lohr and Faissner, 2004). Protein 
analyses carry the advantage of representing the actual metabolic state of the 
cell, however, they are challenging (Lohr and Faissner, 2004). While serum 
proteomic analysis of ECM proteins in AP has been undertaken (Lohr et al., 
1999), tissue proteomics remains largely underexplored due to the technical 
challenges associated with it (Wilson, 2010).  
 
1.10 Hypothesis and outline of thesis 
It is hypothesized that the high level of connectivity of HBPs demonstrated in 
previous genome-wide studies would also be true in the normal pancreas and in 
some of its disease states. If this hypothesis is true, by virtue of their binding to 
heparin, HBPs would provide an easily accessible sub-proteome, which could be 
mined for biomarkers and drug targets in pancreatic diseases. The first 
objective of this thesis is to undertake a comprehensive meta-analysis of mRNA 
datasets in the major pancreatic diseases. Chapter 2 describes this in silico study 
(Nunes et al., 2013). While this work provides strong support for the 
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hypothesis, it assumes mRNA to be representative of translation and that the 
existing list of HBPs (Ori et al., 2011) to be reasonably representative of those 
expressed in the pancreas.  Both these assumptions could undermine the 
validity of the conclusions drawn from the meta-analysis of mRNA. 
 
Consequently, the second objective of this thesis is to implement an affinity 
proteomic strategy that would tackle in a systematic way the identification of 
new HBPs in the normal pancreas (NP) and in AP. Biases often derive from 
experimental compromises necessary to ensure the high throughput of the 
procedures (Mackay et al., 2007). Further biases can arise from the disruption 
of cellular anatomical structures, typically in pull-down or affinity experiments 
that are performed on cell extracts. Also in this case, the information on the 
original sub-cellular localisation of interacting partners is lost, increasing, 
therefore, the probability of observing spurious interactions not likely to occur 
in vivo. Bearing this in mind, in Chapter 3, an affinity proteomic strategy for the 
identification of HBPs in murine normal pancreas and experimental acute 
pancreatitis was implemented. The strategy was focused on the cell surface and 
extracellular proteome derived from mouse pancreas extracts, the rationale 
being that targeting the compartment where HSPGs are expressed increases the 
probability of identifying more relevant binding partners, likely to co-localise 
with HS in vivo. Despite the need for validation of the newly described 
interactions, the identification of new heparin/HS binding partners can help to 
unravel new molecular circuits involving HSPGs. This chapter also describes the 
construction and network-level analysis of the heparin interactome, i.e. the 
protein-protein interactions of the HBPs. The heparin interactome was built 
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using the HBPs from the heparin affinity proteomics experimental data. This 
dataset was then used to investigate the network properties, and functional and 
structural features that characterise the heparin interactome. Network level 
approaches have been widely used in the last decade for the analysis of protein-
protein interactions (PPIs) (Jeong et al., 2001), transcription factor binding 
specifities (Grove et al., 2009), metabolic pathways (Ideker et al., 2001), and 
signalling pathways (Linding et al., 2007), revolutionising the representation 
and interpretation of biological processes. The network-level analysis provides 
important general functional insights on HBPs that could be extremely valuable 
in the design of future experiments, and also exemplifies a new way of 
investigating protein-GAG interactions that has the potential for widespread 
application in the field of glycobiology. 
Chapter 4 discusses the findings of this thesis and compares the in silico and 
experimental work. It focuses on some of the key pathways relevant to 
pancreatic homeostasis in health and in acute pancreatitis and explores the 
potential role of candidate HBPs as biomarkers and drug targets.  
The main body of this thesis has been presented in the form of 2 manuscripts. 
The in silico work has been published (Nunes et al., 2013) and has been included 
in Chapter 2. The proteomics work is a manuscript in preparation and has been 
included in Chapter 3. The papers included are in the journal-specific submitted 
format with modifications for the purpose of convenience. The font style and 
size are identical to rest of the thesis text. Sections, tables and figures have been 
numbered and included in the table of contents. As the supplemental data for 
the manuscript included in Chapter 3 are large, these have been copied to the 
attached CD. The proteomics data has been uploaded into PRIDE database 
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(http://www.ebi.ac.uk/pride/archive/)(Vizcaino et al., 2013). 
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Chapter 2 – In silico analyses 
 
2.1 Introduction 
Extracellular proteins have played a central role in vertebrate evolution 
(Huxley-Jones et al., 2009). A genome-wide study has shown that these proteins 
showed a significant expansion with a concomitant expansion in function as the 
complexity of organisms increased (Vogel and Chothia, 2006). It was 
subsequently shown that among the extracellular proteins, HBPs form 
important functional modules within the extracellular space (Ori et al., 2011).  
This in silico analysis was undertaken to test the first hypothesis (Chapter 1; 
1.9) that HBPs would form important functional modules in the extracellular 
space when investigating the normal pancreas (NP) and major pancreatic 
diseases namely acute pancreatitis, chronic pancreatitis and pancreatic ductal 
adenocarcinoma. If this is true, HBPs, by virtue of their binding to heparin, 
would provide an easily accessible repository within the extracellular space for 
biomarker discovery and drug development. In this study, we used mRNA 
expression as a proxy for protein and identified putative HBPs in NP, AP, CP and 
PDAC. Network analysis of the putative HBP interacting networks showed that 
HBPs form important, well-connected modules within the extracellular space in 
the normal pancreas, AP, CP and PDAC. The analysis also identified HBP 
candidates as potential biomarkers and drug targets in these diseases (Nunes et 
al., 2013). These candidates were further investigated using a literature-mining 
tool, Pubmatrix (Becker et al., 2003), to assign functional relevance to HBPs in 
the major pancreatic diseases. While this work provides strong support for the 
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hypothesis, it assumes mRNA to be representative of translation and that the 
existing list of HBPs to be reasonably representative of those expressed in the 
pancreas.  Building on the results from the in silico analysis, it was necessary to 
implement an affinity proteomic strategy that would tackle in a systematic way 
the identification of new HBPs in the normal pancreas (NP) and in the major 
pancreatic diseases. In the first instance, it was decided to perform the 
proteomics experiments in NP and an experimental model of one of the major 
pancreatic diseases. As AP affords the benefit of several time-tested 
experimental models (Chapter 1; 1.4), it was decided to undertake the affinity 
proteomics experiments in NP and experimental murine AP (Chapter 3). 
 
2.2 Various terms explained 
 
2.2.1 Node  
A node is a gene, mRNA or protein. In this study it refers to an HBP. 
 
2.2.2 Edge  
An edge is an interaction between 2 nodes. 
 
2.2.3 Degree 
The most elementary characteristic of a node is its degree or connectivity. This 
is denoted by ‘k’ and informs about the number of links a node has to other 
nodes, e.g., in an undirected network (Fig. 2.1A), node A has degree k = 4. In 
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directed networks in which each edge has a selected direction (Fig 2.1B) there is 
an incoming degree, kin, which represents the number of edges that point to a 
node. Similarly, an outgoing degree kout, denotes the number of edges that start 
from it. Node A has kin = 4 and kout = 1 (Fig 2.1B). An undirected network with N 
nodes and L links or edges is characterized by an average degree <k> = 2L/N 
(where <> denotes the average). 
 
2.2.4 Interactome  
An interactome is an interacting network. 
 
2.2.5 Plugin 
A plugin is a tool used to analyse a network. 
 
2.2.6 Number of connected components 
In undirected networks, two nodes are connected if there is a path of edges 
between them. Within a network, all nodes that are pairwise connected form a 
connected component. The number of connected components indicates the 
connectivity of a network – a lower number of connected components suggests 
a stronger connectivity (Fig. 2.2). 
 
2.2.7 Clustering coefficient 
If ‘n’ is the number of nodes, the clustering coefficient is a ratio N / M, where ‘N’ 
is the number of edges between the neighbours of n, and ‘M’ is the maximum 
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number of edges that could possibly exist between the neighbors of n. The 
clustering coefficient of a node is always a number between 0 and 1. 
 
 
Figure 2.1: Network connectivity A) in an undirected network, node A has degree k = 
4. B) in a directed network Node A has an incoming degree, kin = 4 and an outgoing 
degree, kout = 1. 
 
The network clustering coefficient is the average of the clustering coefficients 
for all nodes in the network (Barabasi and Oltvai, 2004, Watts and Strogatz, 
1998). Nodes with less than two neighbors are assumed to have a clustering 
coefficient of 0.  
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In undirected networks, the clustering coefficient Cn of a node n is defined by 
the equation Cn = 2en/(kn (kn-1)), where kn is the number of neighbors of n and en 
is the number of connected pairs between all. 
In directed networks, the equation is Cn = en/(kn (kn-1)) neighbors of n. 
 
 
Figure 2.2: Number of connected components A) Node A, which is connected to 
Node B via 2 edges, is less well connected as compared to B) Node E, which is 
connected to Node B via a single edge 
 
2.2.8 Gene ontology 
Gene ontology (GO) is a major bioinformatics initiative to standardize gene and 
gene product attributes across species and covers three major domains namely 
biological process (BP), cellular component (CC) and molecular function (MF).  
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2.2.9 Canonical pathway 
Canonical pathways are well characterized metabolic and cell signalling 
pathways that have been curated from original publications. These do not 
change according to data input. 
 
2.3 Bioinformatics pipeline 
A number of bioinformatics resources were used for network construction and 
data analysis (Fig. 2.3) 
 
 
 
 
Figure 2.3: Bioinformatics pipeline used to analyse the role of HBPs in the NP, AP, 
CP and PDAC. Networks of HBPs were constructed using interactions from the 
STRING database. Canonical pathways analyses (Ingenuity Pathways Analysis), 
Gene ontology enrichment and top clusters using AllegroMCODE (Cytoscape 2.8.1) 
were some of the bioinformatics tools used to identify potential biomarkers and drug 
targets. 
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2.4.1 Abstract 
 
Background: The cellular microenvironment plays an important role in the 
regulation of homeostasis and is a source of potential biomarkers and drug 
targets. In a genome-wide analysis the extracellular proteins that bind to 
heparin (HBPs) have been shown to form highly modular and interconnected 
extracellular protein regulatory networks. Using a systems biology approach, 
we have investigated the role of HBP networks in the normal pancreas and 
pancreatic digestive diseases. 
 
Methods: Lists of mRNAs encoding for HBPs associated with the normal 
pancreas (NP), acute pancreatitis (AP), chronic pancreatitis (CP) and pancreatic 
ductal adenocarcinoma (PDAC) were obtained using public databases and 
publications. Networks of the putative protein interactomes derived from 
mRNA expression data of HBPs were built and analysed using cluster analysis, 
gene ontology term enrichment and canonical pathways analysis. 
 
Results: The extracellular heparin-binding putative protein interactomes in the 
pancreas were better connected than their non heparin-binding counterparts, 
having higher clustering coefficients in the normal pancreas (0.273), acute 
pancreatitis (0.457), chronic pancreatitis (0.329) and pancreatic ductal 
adenocarcinoma (0.269). ‘Hepatic Fibrosis / Hepatic Stellate Cell Activation’ 
appears to be a significant canonical pathway in pancreatic homeostasis in 
health and disease with a large number of important HBPs. 
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Conclusions: Our analyses clearly demonstrate that HBPs form disease-specific 
and highly connected networks that can be explored for potential biomarkers 
and as collective drug targets via the modification of heparin binding properties.  
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2.4.2 Introduction: 
The microenvironment of tissue matrix, cells and bioactive molecules 
plays an important role in the regulation of biological homeostasis. The 
extracellular matrix (ECM) is a dynamic three-dimensional medium and its 
biophysical and biochemical properties vary in health and disease (Hynes, 
2009). There is an abnormal accumulation of ECM in inflammation and cancer 
that increases the stiffness of the tissue and leads to increased tissue hypoxia 
(Kong and Mooney, 2007). The altered ECM may also affect the transmission of 
bioactive molecules in the microenvironment and may thereby influence cell 
signalling (Duchesne et al., 2012). Within the microenvironment of the 
pancreas, the pancreatic stellate cell (PSC) is a specialised cell, which plays an 
important role in maintaining the architecture of the pancreas and the 
composition of the ECM. The PSC secretes excessive amounts of ECM proteins in 
pancreatic diseases, which increase fibrosis within the tissue and contribute to 
ECM stiffness (Apte et al., 2012). 
Extracellular proteins, including those of the ECM, are suggested to have played 
a central role in vertebrate evolution (Huxley-Jones et al., 2009). Moreover, a 
genome-wide analysis by Vogel and Chothia has shown that these proteins 
expanded significantly with a concomitant expansion in their contribution to 
function as the biological complexity of organisms increased (Vogel and Chothia, 
2006). Subsequently, Ori et al. demonstrated that within the extracellular 
proteins those that bind to heparin, form an important integrated functional 
network (Ori et al., 2011). Heparin is used as an experimental proxy for the 
related cellular heparan sulfate (HS) for practical reasons of convenience and 
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cost and heparin affinity chromatography affords a tool to analyse HBPs. HS is a 
linear polysaccharide in the ECM containing a characteristic disaccharide-
repeating unit and belongs to the family of glycosaminoglycans. HS chains 
attach to core proteins to form HS proteoglycans and are major components of 
the pericellular matrix/glycocalyx and of the ECM (Ori et al., 2008). Many HBPs 
are important signalling molecules in the microenvironment and regulate 
fundamental biological processes such as cell adhesion, differentiation, 
proliferation and migration (Ori et al., 2011).  
The pancreas has important exocrine and endocrine functions that 
develop from endodermal cells in the embryonic foregut (Zaret and Grompe, 
2008). AP, CP and PDAC are major diseases of the pancreas that pose diagnostic 
and therapeutic challenges. AP is acute inflammation of the pancreas and is 
mainly caused by gallstones and alcohol (Pandol et al., 2007). Although most 
episodes are mild and self-limiting, the severe form of the disease is associated 
with a high mortality (Schneider et al., 2010). In the absence of specific 
treatments for AP, therapy is mainly supportive. CP is a progressive 
inflammatory disease of the pancreas and a known risk factor for pancreatic 
cancer (Lowenfels et al., 1993). PDAC and CP present with similar signs and 
symptoms and are associated with an intense fibrosis. These pose a diagnostic 
dilemma, as they are difficult to distinguish clinically and radiologically 
(Johnson and Outwater, 1999). PDAC is a major cause of cancer death and is one 
of the most difficult cancers to treat (Thomas et al., 2010). Surgical resection 
continues to form the mainstay of treatment in about 15-20% of patients, the 
rest presenting with unresectable disease (Alexakis et al., 2004). There is a need 
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to develop reliable biomarkers for early detection and more effective drugs in 
the management of PDAC 
On a genome-wide basis, HBPs have been shown collectively to play a 
pivotal role in driving biological complexity and influence fundamental 
processes underlying complex diseases (Ori et al., 2011). We hypothesized that 
HBPs would form well-connected modules, which play important regulatory 
roles in the extracellular space in the normal pancreas and in some of its disease 
states. If this hypothesis were true, by virtue of their binding to heparin, HBPs 
would provide an easily accessible sub-proteome, which could be mined for 
biomarkers and drug targets in pancreatic diseases. 
Using mRNA expression as a proxy for protein, we have identified the 
putative HBPs in normal pancreas (NP) and in three pancreatic diseases (AP, CP 
and PDAC).  Analyses of the putative interactomes of the HBPs demonstrate that 
they indeed form an important integrated functional network. Many of the 
putative HBPs are recognised as regulating fundamental biological processes 
underlying pancreatic physiology and pathology. The analyses also identify 
potential biomarkers and drug targets in pancreatic diseases, such as fibroblast 
growth factor receptor -2 (FGFR2), which may be explored in pancreatic stellate 
cell (PSC) targeted therapy in PDAC. 
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2.4.3 Materials and methods: 
2.4.3.1 Building putative protein interactomes for the pancreas 
Lists of genes and gene products associated with NP, AP, CP and PDAC 
Lists of mRNAs and proteins associated with NP, CP and PDAC were 
obtained using the Pancreatic Expression Database. This database is a 
comprehensive open-access mining tool for large-scale genomic, transcriptomic 
and proteomic datasets (Chelala et al., 2007, Cutts et al., 2011). The lists were 
generated using the filters ‘Normal Pancreas’, ‘Chronic Pancreatitis’, and 
‘Pancreatic Ductal Adenocarcinoma’. A list of genes associated with AP was 
obtained from the NCBI ‘Gene’ database using the search term “Acute 
Pancreatitis”.  
  
2.4.3.2 Lists of HBPs associated with NP, AP, CP and PDAC 
A list of 435 HBPs was obtained from supplementary information in Ori 
et al, 2011 (Ori et al., 2011). This list was built using a combination of literature 
curation, data retrieval from public databases and experimental data using an 
affinity proteomic approach. The ‘compare’ tool of Ingenuity Pathways Analysis 
(IPA, Ingenuity Systems, www.ingenuity.com) was used to generate lists of 
HBPs associated with NP, AP, CP and PDAC, derived from the IPA Knowledge 
Base, a repository of biological interactions and functional annotations that are 
reviewed regularly for accuracy. 
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2.4.3.3 Interactions and construction of networks of HBPs 
Lists of interactions between HBPs were obtained using the online 
database resource ‘Search Tool for the Retrieval of Interacting Genes’ (STRING). 
STRING 9.0 is a database of known and predicted functional interactions and 
served as a ‘one-stop’ comprehensive resource that could be easily used with 
Cytoscape (Szklarczyk et al., 2011). The interactions in STRING are provided 
with a probabilistic confidence score that is an estimate of how likely an 
interaction describes a functional linkage between two proteins. A higher score 
indicating a higher confidence is given when more than one type of information 
supports a given association. Only interactions with the highest confidence 
score (0.900 and above) were used to build networks using Cytoscape 2.8.1, 
which is an open source, Java based bioinformatics package for biological 
network visualization (Smoot et al., 2011). The resulting networks were termed 
‘putative protein interactomes’, because the HBP lists were derived from mRNA 
expression data and the interactions between the listed entities were retrieved 
from STRING. As for nearly any expression dataset used for in silico network 
analysis, there was uncertainty with respect to the actual presence of the 
expressed proteins and the potential interactions in a cultured cell or in a tissue. 
However, correspondence between the major protein and mRNA expression 
pools and the resistance of general network properties to slight variations in the 
connectivity of each component support the legitimacy of this widely used 
approach (Cirillo, 2012). In the putative protein interactomes, HBPs or ‘nodes’ 
that are unique to a dataset are coloured red, while the rest of the HBPs are 
coloured grey. Black lines connecting the HBPs denote the interactions or 
‘edges’. 
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2.4.3.4 Network Analysis 
2.4.3.4.1 Network parameters 
Additional ‘plugins’ or tools to analyse networks are available in Cytoscape. The 
networks were treated as undirected and the following parameters were 
computed using the ‘NetworkAnalyzer’ plugin (Assenov et al., 2008): diameter, 
average number of neighbours, number of connected pairs of nodes, node 
degree, average clustering coefficient, topological coefficient, and shortest path 
length. We used the ‘clustering coefficient’ and ‘number of connected 
components’ as measures of network connectivity. Clustering coefficient is a 
ratio of the number of edges between neighboring nodes and the maximum 
number of edges that could possibly exist between them. The clustering 
coefficient of a node is always a number between 0 and 1. The clustering 
coefficient of a network is the average of the clustering coefficients for all nodes 
in the network. In undirected networks, two nodes are connected if there is a 
path of edges between them. Within a network, all nodes that are connected 
pairwise form connected components. A high clustering coefficient and a low 
number of connected components are present in well-connected 
networks(Barzel and Biham, 2009). Clusters, or highly interconnected hubs of 
nodes within the networks, were identified with the ‘AllegroMCODE’ plugin. 
 
2.4.3.4.2 Comparing the connectivity of the heparin-binding putative protein 
interactomes with other pancreatic putative protein interactomes 
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Clustering coefficients of extracellular putative protein interactomes in the 
normal and diseased pancreas were compared in order to ascertain if the 
heparin-binding putative protein interactomes formed important modules 
within the extracellular space in the pancreas. The lists of all extracellular 
proteins were extracted by applying filters based on Gene Ontology (GO) 
cellular component terms to the lists. This was performed using the ‘Database 
for annotation, visualization and integrated discovery’ (DAVID) and the GO FAT 
annotation. DAVID 6.7 is a bioinformatics resource that extracts biological 
meaning from gene / protein lists (Huang da et al., 2009). GO FAT is a subset of 
the GO term set that is created by filtering out the broadest ontology terms, so 
as not to overshadow more specific ones. The terms used were: GO:0005576 
(extracellular region), GO:0005615 (extracellular space), GO:003102 
(extracellular matrix- ECM) and GO:0005604 (basement membrane).  The non-
HBP lists were generated by subtraction of HBP names from the datasets of all 
extracellular proteins. The extracellular non heparin-binding putative protein 
interactome (Ec_not hepint) and the extracellular heparin-binding putative 
protein interactome (Ec_hepint) for NP, AP, CP and PDAC, were built using the 
interaction data retrieved from the STRING database and their clustering 
coefficients were compared. 
 
2.4.3.4.3 Comparison with random networks 
The heparin-binding putative protein interactomes (Ec_hepint) in NP, 
AP, CP and PDAC were each compared with 10 of their corresponding degree-
preserving randomised versions in order to determine whether the network 
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parameters arising from the interactions of the putative HBPs were random. 
This is a quality assurance exercise. The randomised networks 
(Ec_hepint_random) were generated, by shuffling the edges of the respective 
heparin-binding putative protein interactomes, using the ‘Random Networks’ 
plugin with Cytoscape. The average clustering coefficient of Ec_hepint was 
compared with the average clustering coefficient of the corresponding random 
network in NP, AP, CP and PDAC. A network is deemed to be well connected if 
its average clustering coefficient is significantly higher than that of its 
corresponding random networks.  
A Shapiro-Wilk test was performed to test if the clustering coefficients 
were normally distributed (data are considered to be normally distributed if 
p>0.05)(Henderson, 2006). The clustering coefficients of the various networks 
were then compared using the independent t-test; p<0.05 was considered to be 
significant. The statistical analyses were performed using SPSS version 20. 
 
2.4.3.5 Identification of potential biomarkers and therapeutic targets  
2.4.3.5.1 Canonical pathways analysis 
 Canonical pathways are well characterized metabolic and cell signalling 
pathways that have been curated from original publications and do not change 
according to data input. Canonical pathways analysis used the IPA library of 
canonical pathways to identify those that were most significant to each of the 
datasets of HBPs associated with NP, AP, CP and PDAC. The significance of the 
association between the datasets and the canonical pathway was measured by 
calculating the p-value using Fisher’s exact test to determine the probability of 
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the association between the HBPs in the dataset and the canonical pathway. 
Canonical pathways analysis is a useful tool, when used on its own or in 
conjunction with other tools such as the Cytoscape plugin AllegroMCODE, to 
identify potential biomarkers and drug targets. It also helps identify biological 
pathways that play important roles in homeostasis and complex diseases. 
 
2.4.3.5.2 Functional Analysis of HBPs 
Functional analyses of the datasets were performed using tools for GO 
term enrichment. GO is a major bioinformatics initiative to standardize gene 
and gene product attributes across species and covers three major domains 
namely biological process (BP), cellular component (CC) and molecular function 
(MF). GO term enrichment for the lists of HBPs associated with NP, AP, CP and 
PDAC was performed using DAVID and the GO FAT annotation. GO term 
enrichment provides biological context to the HBP datasets and so helps to 
identify potential biomarkers and drug targets. 
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2.4.4 Results:  
2.4.4.1 Building putative protein interactomes for the pancreas 
The HBPs were identified using the Pancreatic Expression Database, the 
NCBI ‘Gene’ database and a list of HBPs from Ori et al, 2011 (Ori et al., 2011). 
The lists of HBPs associated with NP (n= 115), AP (n= 31), CP (n=112) and 
PDAC (n=141) are in Supplementary Tables 1-4. A number of HBPs were 
uniquely associated with the NP (n=1), AP (n=16), CP (n=12) and PDAC (n=23) 
datasets in our study (Table 2.3.1). The lists of HBPs were used to obtain 
interactions from STRING, which were then imported into Cytoscape to build 
heparin-binding putative protein interactomes. As a result of the stringent 
criteria adopted, for interaction selection, some HBPs from the datasets in our 
study are notably absent from the interacting networks. The key features of the 
putative protein interactomes are illustrated with the HBPs identified in the 
PDAC-associated expression data (Figure 2.3.1).  HBPs or ‘nodes’ that are 
unique to the PDAC dataset in the study are coloured red, while the rest of the 
HBPs are coloured grey. Black lines connecting the HBPs denote the interactions 
or ‘edges’. The regulatory importance of these interactomes was quantified by 
network analysis. 
 
2.4.4.2 Network analysis 
The topological parameters of the heparin-binding putative protein 
interactomes associated with NP, AP, CP and PDAC were obtained using the 
‘NetworkAnalyzer’ plugin in Cytoscape. A high clustering coefficient compared 
with those of its corresponding random networks and a lower number of 
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connected components indicate a strong interconnectivity of a network (Dong 
and Horvath, 2007, Barzel and Biham, 2009).  HBPs form highly interconnected 
networks in the normal pancreas with four connected components and a high 
clustering coefficient of 0.273. The heparin-binding putative protein 
interactome (Ec_hepint) of the normal pancreas was better interconnected than 
its corresponding random network (Ec_hepint_random) and importantly, of the 
extracellular proteins minus the HBPs (Ec_not_hepint) (Figure. 2.3.2). This 
indicates that the HBPs indeed form a densely interconnected network module 
in the extracellular space in the normal pancreas. 
 
The heparin-binding putative protein interactomes in AP, CP and PDAC were 
also found to be highly interconnected with one, three and five connected 
components. They also have high clustering coefficients of 0.457, 0.329 and 
0.269 (Figure 2.3.2). Comparing the topological parameters of the HBP 
networks with the other protein networks in the pancreas, Ec_hepint in AP, CP 
and PDAC were also better interconnected than their corresponding random 
networks (Ec_hepint_random) and the extracellular non heparin-binding 
putative protein interactomes (Figure 2.3.2). Thus, as for NP, the heparin-
binding putative protein interactomes of AP, CP and PDAC also formed highly 
interconnected modules of extracellular proteins. 
 
To determine if the network parameters between HBPs arose randomly, 
the‘Random Networks’ plugin was used to perform shuffles on the heparin-
binding putative protein interactomes to generate degree-preserving random 
networks of HBPs (Ec_hepint_random) (Materials and Methods). The clustering 
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coefficients of the various networks were normally distributed (Shapiro-Wilk 
test, Supplementary Table 5). In NP, AP, CP and PDAC the respective Ec_hepint 
had a higher clustering coefficient than the corresponding Ec_hepint_random 
(Figure 2.3.2).  Therefore, these analyses demonstrated that the interactions 
and network parameters for the NP, AP, CP and PDAC heparin-binding putative 
protein interactomes did not arise randomly. The dense networks of HBPs in 
normal and in pancreatic disease exhibit properties similar to highly connected 
networks, sometimes termed ‘small world’ networks, and indeed represent real 
and probably important functional modules (Watts and Strogatz, 1998).  
 
2.4.4.3 Identification of potential biomarkers and therapeutic targets 
Canonical pathways analysis, cluster analysis and GO enrichment were used to 
identify potential biomarkers and therapeutic targets. 
 
2.4.4.3.1 Canonical Pathways 
Canonical pathways analysis provides insights into well-defined biological 
regulatory processes and signalling cascades underlying normal organ 
physiology and diseases. HBPs are enriched in a number of important biological 
pathways (Figure 2.3.3). ‘Hepatic Fibrosis / Hepatic Stellate Cell Activation’ is 
the top canonical pathway linked to HBPs associated with NP (p=7.98E-16, 
16/147 molecules), AP (p=3.32E-18, 12/147 molecules) and PDAC (p=2.57E-18, 
19/147 molecules).  Six HBPs, which are unique to the AP dataset, namely CCl2, 
IFNG, Il6, TNF, TGFβ1 and VEGFA and 2 HBPs that are unique to the PDAC 
dataset in our study, FGFR2 and VEGFB, are linked to this canonical pathway. 
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‘Coagulation System’ (p=3.09E-17, 12/38 molecules) and ‘Intrinsic Prothrombin 
Activation Pathway’ (p=3.03E-14, 10/34 molecules) are other significant 
pathways associated with the PDAC dataset. The top canonical pathway 
associated with CP dataset is the ‘Coagulation System’ pathway (p=1.74E-18, 
12/38 molecules). Other important canonical pathways associated with the CP 
dataset are ‘Intrinsic Prothrombin Activation Pathway’ (p=3.12E-17, 11/34 
molecules) and ‘Hepatic Fibrosis / Hepatic Stellate Cell Activation’ (p=2.52E-13, 
14/147 molecules). Canonical pathways analysis indicates that stellate cells 
play important roles in the pancreas and may be explored further to develop 
cell specific therapies. 
 
2.4.4.3.2 Cluster analysis 
Clusters are groups of highly interconnected nodes. Clusters are scored 
depending on the number of constituent nodes and the edges (interactions) 
between them. Top clusters associated with the HBP networks (Table 2.3.2) 
were generated using the AllegroMCODE plugin in Cytoscape. These top clusters 
were analysed further to explore their potential as biomarkers and drug targets, 
using IPA. Each of the top clusters in NP, AP, CP and PDAC contained HBPs that 
had similar biological functions notably inflammatory response, cell-cell 
signalling and cellular movement, indicating that they were biologically relevant 
(Barabasi and Oltvai, 2004). The top cluster in the AP heparin-binding putative 
protein interactome consists of 6 HBPs unique to the AP HBP dataset, namely 
CCl2, IFNG, Il6, TNF, TGFβ1 and VEGFA (Figure 2.3.4). This cluster also enriches 
to the ‘Hepatic Fibrosis / Hepatic Stellate Cell Activation’ canonical pathway, 
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which as shown above is also the top pathway associated with the AP HBP 
dataset. Thus, the canonical pathways and cluster analyses identify key 
molecules that may lead to biomarkers and drug targets. 
 
2.4.4.3.3 GO term enrichment 
 GO term enrichment provides a means to identify key processes that can be 
attributed to a gene or protein set. The GO terms ‘Response to wounding’ 
(p=3.52E-23), ‘Wound healing’ (p=5.92E-16) and ‘Regulation of body fluids’ 
(p=8.88E-16) are the top terms of the ‘Biological Process sub-ontology' enriched 
by HBPs associated with the normal pancreas. ‘Response to wounding’ 
(p=1.32E-17), ‘Defence response’ (p=1.34E-13) and ‘Leucocyte migration’ 
(p=1.73E-13) are the top terms enriched by HBPs associated with AP. ‘Response 
to wounding’ (p=8.31E-24), ‘Extracellular matrix organisation’ (p=1.90E-15) 
and ‘Wound healing’ (p=5.14E-15) are the top ‘Biological Process’ terms 
enriched by HBPs associated with CP. ‘Response to wounding’ (p=6.15E-25), 
‘Wound healing’ (p=2.52E-15) and ‘Cell adhesion’ (p=3.60E-15) are the top 
‘Biological Process’ terms enriched by HBPs associated with PDAC.   
 
2.4.5 Discussion 
The in silico analyses of putative interactomes of HBPs demonstrate that 
these form highly connected networks in the normal pancreas and in three 
major pancreatic digestive diseases that may define important extracellular 
protein regulatory modules.  This is strongly supported by the high clustering 
coefficients associated with the heparin-binding putative protein interactomes 
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of the normal pancreas, AP, CP and PDAC, compared to their corresponding 
random networks. Moreover, the heparin-binding putative protein interactomes 
have higher clustering coefficients, as compared to the extracellular non 
heparin-binding putative protein interactomes in NP, CP and PDAC (Figure 
2.3.2).  
 Previously, the reductionist approach to drug development has resulted 
in many successful single-target drugs over the past decades, although 
systematic analysis of interactomes has not featured prominently in drug 
design. Single target drugs, however, are less able to combat the complex 
pathologies of inflammatory diseases and cancer, which are regulated by 
multiple and often partly redundant molecular inputs (Leung et al., 2012). This 
difficulty is particularly evident in pancreatic diseases, where there are very few 
specific therapies. In contrast, a holistic ‘Systems Biology’ approach based on 
the heparin interactome may provide small groups of biomarkers and drug 
targets in pancreatic digestive diseases and is complementary to the 
reductionist approach to drug development. Even though the meta-analytical 
approach adopted here assumes mRNA to be representative of translation and 
our knowledge of the nature and functions of specific proteins is incomplete and 
variably informative, there is a plethora of original findings that it behoves us to 
inter-relate. 
These conclusions are also supported by GO term enrichment and 
canonical pathways analysis, since these identified cell-signalling cascades and 
molecular functions that are coherent with NP, AP, CP and PDAC.  For example, 
the top GO term of the sub-ontology Biological Process enriched to HBPs 
associated with AP, CP and PDAC was ‘response to wounding’. Other Biological 
 56 
Process sub-ontology terms significantly enriched to the AP dataset included 
defence response, leukocyte migration, inflammatory response and leukocyte 
migration, which one would associate with an acute inflammatory disease such 
as AP. Leukocytes and neutrophils in particular are known to play an important 
role in AP (Abdulla et al., 2011, Nakamura et al., 2010). The desmoplastic 
reaction associated with CP and PDAC is reflected by the enrichment of GO term 
‘extracellular matrix organization’ to the HBP datasets associated with these 
diseases (Johnson and Outwater, 1999). GO terms such as cell adhesion, blood 
vessel development, vasculature development and regulation of cell migration 
enriched to the PDAC dataset are clearly key processes in cancer.  
Canonical pathways represent well-characterized metabolic and cell-
signalling cascades that have been curated from original literature and do not 
change according to data input. They are important in informing our 
understanding of cell function and predicting cell behaviour (Melas et al., 2011). 
The canonical pathways that are enriched by the HBP datasets in pancreatic 
digestive diseases provide useful insights into important pathways influencing 
these diseases. ‘Hepatic Fibrosis / Hepatic Stellate Cell Activation’ is the top 
canonical pathway linked to the AP and PDAC datasets and is a significant 
pathway in CP. Stellate cells play an important role in inflammatory diseases 
and cancer of the liver as in the pancreas (Xu et al., 2010b, Friedman, 2008, 
Masamune et al., 2009). The presence of a well-defined fibrosis and activation 
pathway associated with the hepatic stellate cell rather than its pancreatic 
counterpart is probably due to the fact that the former was discovered earlier 
and has been studied more extensively (Geerts, 2001). As information relating 
to PSCs evolves, pathways relating to PSC activity may become better defined. 
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Hepatic and pancreatic stellate cells exhibit great similarities, are activated by 
common cytokines and growth factors, and may share a common origin 
(Buchholz et al., 2005, Omary et al., 2007). Experiments relating to PSCs indicate 
that they play an important role in the normal and diseased pancreas 
(Vonlaufen et al., 2007, Algul et al., 2007). These cells maintain normal 
pancreatic architecture, as well as contribute to the increased stiffness of the 
ECM in CP and PDAC by inducing fibrosis (Apte et al., 2012). The increased 
stiffness of the ECM in turn may affect the transmission of signals between cells 
in the pancreatic microenvironment. Thus, HBPs unique to the AP and PDAC 
datasets and also enriched to the ‘Hepatic Fibrosis / Hepatic Stellate Cell 
Activation’ pathway may be explored as potential PSC specific biomarkers and 
drug targets. FGFR2 is a target, which may enable the development of PSC-
directed drug therapy in PDAC. In pancreatic cancer, FGFR2 is over-expressed in 
both cancer cells and the adjacent pancreatic parenchyma (Ishiwata et al., 
1998). Stromal FGF10 (fibroblast growth factor 10) – FGFR2 signalling induces 
migration and invasion in pancreatic cancer cells, and is associated with a poor 
prognosis (Nomura et al., 2008). FGFR2 is uniquely associated with the PDAC 
dataset in our study and this is in the context of a common expression in NP, CP 
and PDAC of two ligands, FGF-3 and FGF-5 (Table 2.3.1 and Supplementary 
Tables 1, 3 and 4). This ligand pair is able to activate both the FGFR2b and 
FGFR2c splice variants (Ornitz et al., 1996). Thus, these data suggest that FGFR2 
inhibitors may be of use in the treatment of PDAC, and these are readily 
available because FGFR2 is already been being explored as a drug target in 
other solid organ tumours (Byron and Pollock, 2009). 
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The top cluster in the AP heparin-binding putative protein interactome is 
also linked with the ‘Hepatic Fibrosis / Hepatic Stellate Cell Activation’ 
canonical pathway. Within this cluster, 6 HBPs namely CCl2, IFNG, IL-6, TNF, 
TGFβ1 and VEGFA are in the AP HBP dataset. Interleukin-6 (IL-6), which is a 
cytokine produced by macrophages and a mediator in the synthesis of acute-
phase proteins, forms the hub of this top cluster. IL-6 has been suggested as a 
therapeutic target in acute pancreatitis and is a well-established drug target in 
other diseases such as rheumatoid arthritis(Nishimoto and Kishimoto, 2006). 
PSCs are stimulated by TGFβ1 and PDGFβ (Apte et al., 2000). The various HBPs 
in the top cluster in AP might be thus used to develop PSC-specific or PSC-
related therapy in AP.  
The property of heparin binding, which defines the regulatory 
importance of HBPs through their physiological interactions with HS, can be 
elegantly exploited in a direct proteomic approach, since heparin affinity 
chromatography is a simple and effective means to extract HBPs from a tissue 
or body fluid (Xiong et al., 2008, Ori et al., 2011).  Therefore, given the clear 
importance of HBPs, a direct analysis of HBPs by proteomics of healthy and 
diseased pancreas is likely to yield substantial insights. 
 
2.4.6 Conclusions 
HBPs are shown to constitute a highly regulatory extracellular sub-
proteome in the normal and diseased pancreas and thus are a likely source of 
targets for therapy and biomarkers.  The present analyses have identified HBPs 
already established as having a role in pancreatic disease, e.g., FGFR2, VEGFA.  
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Importantly, these analyses identify clusters of HBPs working together to 
execute a common function, e.g., Hepatic Stellate Cell activation in AP and PDAC. 
The present work demonstrates the power of systems analysis on meta-
expression data where admitted uncertainty in protein presence and 
interactivity do not limit the ability to produce useful predictions and 
recommendations.  
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Condition Unique HBPs 
 
Common HBPs 
NP AMBP  
 
 
APOE, IL8, IL10, MMP9, 
PRSS1, PRSS3, SOD1 
AP APOA5, CCL2, CXCL10, 
IFNγ, IL6, LIPC, LPL, MBL2, 
MPO, PDGFβ, PON1, PROC, 
SELP, TGFβ1, TNF, VEGFA 
CP AIBG, AKR1B1, COL14A1, 
HP, HRG, HSD17B12, PLG, 
SERPINC1, SOD3, TPSAB1, 
TPSB2, TXN 
PDAC APP, ATP1B3, ATP5A1, C3, 
C6, CCL24, CD47, CTSG, 
CXCL2, CYCS, FGFR2, 
FSTL1, HBEGF, NAV2, 
PCSK6, SEMA5A, SERPINA6, 
SERPINE2, SLC2A2, SLC3A2, 
STEAP4, SYNGR1, VEGFB 
 
Table 2.4.1: Unique and common HBPs associated with NP, CP and PDAC datasets. These were 
obtained using IPA’s comparison tool. 
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 NP AP CP PDAC 
Nodes 10 8 4 16 
Edges 33 24 6 52 
Score 3.3 3 1.5 3.25 
Node IDs ITGB1, COL1A1, 
VTN, ITGA5, 
FN1, ITGB3, 
COL1A2, 
ITGAV, ITGA1, 
TNC 
MMP9, IL8, 
IL10, TNF, 
IFNγ, VEGFA, 
CCL2, IL6, 
TGFβ1 
 
ITGB1, COL1A1, 
COL1A2, ITGA1 
 
ITGB1, COL1A1, 
VTN, SERPINE1, 
ITGA5, FN1, 
ITGB3, COL1A2, 
ITGAV, ITGA1, 
TNC, CLU, 
SERPINA1, 
SERPING1, 
A2M, APP 
 
Table 2.4.2: Top clusters in networks of HBPs associated with NP, AP, CP and PDAC. These 
were identified using ‘AllegroMCODE’ with Cytoscape 2.8.1. HBPs unique to each dataset are 
highlighted in bold. The HBPs within the clusters have similar biological functions. 
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Figure 2.4.1: The heparin-binding putative protein interactome in PDAC constructed using Cytoscape 2.8.1. ‘Nodes’ coloured red are HBPs unique to the 
PDAC dataset in the study. Black lines connecting the HBPs denote ‘edges’ or interactions. As a result of the stringent criteria for selecting interactions, some 
HBPs from the datasets in our study are notably absent from the interacting networks. 
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Figure 2.4.2: Comparison of the clustering coefficients. Clustering coefficients were calculated for 
the pancreatic extracellular heparin binding putative protein interactome (Ec_hepint), the 
corresponding random network (Ec_hepint_random) and the pancreatic extracellular non heparin-
binding putative protein interactome (Ec_not hepint) in NP, AP, CP and PDAC. The Ec_hepint 
describes a densely interconnected network module in the extracellular space in the pancreas with a 
significantly higher clustering coefficient (p<0.05, independent t-test, SPSS) as compared to those of 
the random networks and Ec_not hepint in NP, AP, CP and PDAC.  
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Figure 2.4.3: Comparison of canonical pathways involving HBPs associated with NP, AP, CP 
and PDAC using IPA. The ‘Hepatic Fibrosis / Hepatic Stellate Cell Activation’ pathway is an 
important pathway enriched to the HBP datasets in the normal and diseased pancreas. The ratio of the 
number of HBPs from a particular dataset to the total number of molecules in a canonical pathway is 
indicated beside the corresponding bar. 
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Figure 2.4.4: Top cluster in the AP heparin binding putative protein interactome. The nodes 
coloured orange are uniquely associated with the AP HBP dataset. IL-8 is not unique to the AP HBP 
dataset. IL-6, which is a cytokine produced by macrophages and a mediator in the synthesis of acute-
phase proteins, forms the hub of this cluster. The top cluster in AP enriched to the ‘Hepatic Fibrosis / 
Hepatic Stellate Cell Activation’ canonical pathway (CP). 
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Supplementary Table 1: List of HBPs associated with NP 
 
Symbol Entrez Gene Name 
  
 ABP1  amiloride binding protein 1 (amine oxidase (copper-containing)) 
 AGT  angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 
 AMBP  alpha-1-microglobulin/bikunin precursor 
 ANXA1  annexin A1 
 ANXA2  annexin A2 
 ANXA5  annexin A5 
 APOE  apolipoprotein E 
 APOH  apolipoprotein H (beta-2-glycoprotein I) 
 AQP1  aquaporin 1 (Colton blood group) 
 ARG1  arginase, liver 
 ATP2B1  ATPase, Ca++ transporting, plasma membrane 1 
 B2M  beta-2-microglobulin 
 BACE1  beta-site APP-cleaving enzyme 1 
 BGN  biglycan 
 C4BPA  complement component 4 binding protein, alpha 
 CCL19  chemokine (C-C motif) ligand 19 
 CCL21  chemokine (C-C motif) ligand 21 
 CD36  CD36 molecule (thrombospondin receptor) 
 CEL  carboxyl ester lipase (bile salt-stimulated lipase) 
 CFH  complement factor H 
 CLU  clusterin 
 COL11A1  collagen, type XI, alpha 1 
 COL12A1  collagen, type XII, alpha 1 
 COL1A1  collagen, type I, alpha 1 
 COL1A2  collagen, type I, alpha 2 
 COL2A1  collagen, type II, alpha 1 
 COL3A1  collagen, type III, alpha 1 
 COL4A1  collagen, type IV, alpha 1 
 COL4A2  collagen, type IV, alpha 2 
 COL5A1  collagen, type V, alpha 1 
 COL6A3  collagen, type VI, alpha 3 
 COMP  cartilage oligomeric matrix protein 
 CP  ceruloplasmin (ferroxidase) 
 CTSB  cathepsin B 
 CXCL12  chemokine (C-X-C motif) ligand 12 
 DCC  deleted in colorectal carcinoma 
 ECE1  endothelin converting enzyme 1 
 EFNA1  ephrin-A1 
 ENO1  enolase 1, (alpha) 
 ENPP1  ectonucleotide pyrophosphatase/phosphodiesterase 1 
 F2  coagulation factor II (thrombin) 
 F10  coagulation factor X 
 F11  coagulation factor XI 
 FBN1  fibrillin 1 
 FGA  fibrinogen alpha chain 
 FGB  fibrinogen beta chain 
 FGF3  fibroblast growth factor 3 
 FGF5  fibroblast growth factor 5 
 FGG  fibrinogen gamma chain 
 FLT1  fms-related tyrosine kinase 1  
 FN1  fibronectin 1 
 FST  follistatin 
 GJB1  gap junction protein, beta 1, 32kDa 
 69 
 GPNMB  glycoprotein (transmembrane) nmb 
 GSN  gelsolin 
 HDGF  hepatoma-derived growth factor 
 HSPG2  heparan sulfate proteoglycan 2 
 IGFBP2  insulin-like growth factor binding protein 2, 36kDa 
 IGFBP3  insulin-like growth factor binding protein 3 
 IGFBP5  insulin-like growth factor binding protein 5 
 IHH  Indian hedgehog 
 IL3  interleukin 3 (colony-stimulating factor, multiple) 
 IL8  interleukin 8 
 IL10  interleukin 10 
 INHBA  inhibin, beta A 
 ITGA1  integrin, alpha 1 
 ITGA5  integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
 ITGAV  integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) 
 ITGB1  integrin, beta 1  
 ITGB3  integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 
 KAL1  Kallmann syndrome 1 sequence 
 LAMA2  laminin, alpha 2 
 LAMA3  laminin, alpha 3 
 LAMC2  laminin, gamma 2 
 LTBP1  latent transforming growth factor beta binding protein 1 
 LTF  lactotransferrin 
 MDK  midkine (neurite growth-promoting factor 2) 
 MET  met proto-oncogene (hepatocyte growth factor receptor) 
 MMP2  matrix metallopeptidase 2  
 MMP7  matrix metallopeptidase 7 (matrilysin, uterine) 
 MMP9  matrix metallopeptidase 9  
 MMP14  matrix metallopeptidase 14 (membrane-inserted) 
 MYL9  myosin, light chain 9, regulatory 
 NT5E  5'-nucleotidase, ecto (CD73) 
 OCLN   occludin 
 P4HB  prolyl 4-hydroxylase, beta polypeptide 
 PEBP1  phosphatidylethanolamine binding protein 1 
 PLAT  plasminogen activator, tissue 
 PLAU  plasminogen activator, urokinase 
 POSTN  periostin, osteoblast specific factor 
 PRDX4  peroxiredoxin 4 
 PRELP  proline/arginine-rich end leucine-rich repeat protein 
 PRSS1  protease, serine, 1 (trypsin 1) 
 PRSS3  protease, serine, 1 (trypsin 1) 
 PTPRC  protein tyrosine phosphatase, receptor type, C 
 RPL22  ribosomal protein L22 
 SERPINA1  serpin peptidase inhibitor, clade A, member 1 
 SERPINA3  serpin peptidase inhibitor, clade A, member 3 
 SERPINA5  serpin peptidase inhibitor, clade A, member 5 
 SERPINE1  serpin peptidase inhibitor, clade E, member 1 
 SERPING1  serpin peptidase inhibitor, clade G, member 1 
 SLC39A4  solute carrier family 39, member 4 
 SLC4A4  solute carrier family 4, sodium bicarbonate cotransporter, member 4 
 SLPI  secretory leukocyte peptidase inhibitor 
 SNCA  synuclein, alpha (non A4 component of amyloid precursor) 
 SOD1  superoxide dismutase 1, soluble 
 TGM2  transglutaminase 2  
 THBS1  thrombospondin 1 
 THBS2  thrombospondin 2 
 THBS4  thrombospondin 4 
 TNC  tenascin C 
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 TNFAIP6  tumor necrosis factor, alpha-induced protein 6 
 TNXB  tenascin XB 
 TTR  transthyretin 
 VTN  vitronectin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 71 
Supplementary Table 2: List of HBPs associated with AP 
Symbol Entrez Gene Name 
  
 A2M  alpha-2-macroglobulin 
 APOA5  apolipoprotein A-V 
 APOE  apolipoprotein E 
 CCL2  chemokine (C-C motif) ligand 2 
 CTSB  cathepsin B 
 CX3CL1  chemokine (C-X3-C motif) ligand 1 
 CXCL10  chemokine (C-X-C motif) ligand 10 
 HMGB1  high-mobility group box 1 
 IFNG  interferon, gamma 
 IL6  interleukin 6 (interferon, beta 2) 
 IL8  interleukin 8 
 IL10  interleukin 10 
 LIPC  lipase, hepatic 
 LPL  lipoprotein lipase 
 MBL2  mannose-binding lectin (protein C) 2, soluble 
 MET  met proto-oncogene (hepatocyte growth factor receptor) 
 MIF  macrophage migration inhibitory factor (glycosylation-inhibiting factor) 
 MMP9  matrix metallopeptidase 9  
 MPO  myeloperoxidase 
 PDGFB  platelet-derived growth factor beta polypeptide  
 PON1  paraoxonase 1 
 PROC  protein C (inactivator of coagulation factors Va and VIIIa) 
 PRSS1  protease, serine, 1 (trypsin 1) 
 PRSS3  protease, serine, 1 (trypsin 1) 
 SELP  selectin P (granule membrane protein 140kDa, antigen CD62) 
 SERPINA1  serpin peptidase inhibitor, clade A, member 1 
 SOD1  superoxide dismutase 1, soluble 
 TF  transferrin 
 TGFβ1  transforming growth factor, beta 1 
 TNF  tumor necrosis factor 
 VEGFA  vascular endothelial growth factor A 
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Supplementary Table 3: List of HBPs associated with CP 
 
Symbol Entrez Gene Name 
  A1BG  alpha-1-B glycoprotein 
 A2M  alpha-2-macroglobulin 
 ABP1  amiloride binding protein 1 (amine oxidase (copper-containing)) 
 ADAMTS1  ADAM metallopeptidase with thrombospondin type 1 motif, 1 
 AGT  angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 
 AKR1B1  aldo-keto reductase family 1, member B1 (aldose reductase) 
 ANXA1  annexin A1 
 ANXA2  annexin A2 
 ANXA5  annexin A5 
 APOE  apolipoprotein E 
 APOH  apolipoprotein H (beta-2-glycoprotein I) 
 AQP1  aquaporin 1 (Colton blood group) 
 ARG1  arginase, liver 
 ATP2B1  ATPase, Ca++ transporting, plasma membrane 1 
 B2M  beta-2-microglobulin 
 BGN  biglycan 
 C9  complement component 9 
 C4BPA  complement component 4 binding protein, alpha 
 CCL19  chemokine (C-C motif) ligand 19 
 CCL21  chemokine (C-C motif) ligand 21 
 CD36  CD36 molecule (thrombospondin receptor) 
 CEL  carboxyl ester lipase (bile salt-stimulated lipase) 
 CFH  complement factor H 
 CLU  clusterin 
 COL11A1  collagen, type XI, alpha 1 
 COL14A1  collagen, type XIV, alpha 1 
 COL1A1  collagen, type I, alpha 1 
 COL1A2  collagen, type I, alpha 2 
 COL2A1  collagen, type II, alpha 1 
 COL3A1  collagen, type III, alpha 1 
 COL4A1  collagen, type IV, alpha 1 
 COL4A2  collagen, type IV, alpha 2 
 COL5A1  collagen, type V, alpha 1 
 COL6A3  collagen, type VI, alpha 3 
 COMP  cartilage oligomeric matrix protein 
 CP  ceruloplasmin (ferroxidase) 
 CXCL12  chemokine (C-X-C motif) ligand 12 
 ECE1  endothelin converting enzyme 1 
 ENO1  enolase 1, (alpha) 
 ENPP1  ectonucleotide pyrophosphatase/phosphodiesterase 1 
 F2  coagulation factor II (thrombin) 
 F10  coagulation factor X 
 F11  coagulation factor XI 
 FBN1  fibrillin 1 
 FGA  fibrinogen alpha chain 
 FGB  fibrinogen beta chain 
 FGF3  fibroblast growth factor 3 
 FGF5  fibroblast growth factor 5 
 FGG  fibrinogen gamma chain 
 FN1  fibronectin 1 
 FST  follistatin 
 GJB1  gap junction protein, beta 1, 32kDa 
 GPNMB  glycoprotein (transmembrane) nmb 
 GSN  gelsolin 
 HP  haptoglobin 
 73 
 HRG  histidine-rich glycoprotein 
 HSD17B12  hydroxysteroid (17-beta) dehydrogenase 12 
 HSPG2  heparan sulfate proteoglycan 2 
 IGFBP2  insulin-like growth factor binding protein 2, 36kDa 
 IGFBP3  insulin-like growth factor binding protein 3 
 IGFBP5  insulin-like growth factor binding protein 5 
 IGFBP6  insulin-like growth factor binding protein 6 
 IHH  Indian hedgehog 
 IL3  interleukin 3 (colony-stimulating factor, multiple) 
 IL8  interleukin 8 
 IL10  interleukin 10 
 INHBA  inhibin, beta A 
 ITGA1  integrin, alpha 1 
 ITGA5  integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
 ITGB1  integrin, beta 1 (fibronectin receptor, beta polypeptide) 
 LAMA2  laminin, alpha 2 
 LAMA3  laminin, alpha 3 
 LAMC2  laminin, gamma 2 
 LTBP1  latent transforming growth factor beta binding protein 1 
 LTF  lactotransferrin 
 MDK  midkine (neurite growth-promoting factor 2) 
 MIF  macrophage migration inhibitory factor (glycosylation-inhibiting factor) 
 MMP9  matrix metallopeptidase 9  
 MYL9  myosin, light chain 9, regulatory 
 NT5E  5'-nucleotidase, ecto (CD73) 
 OCLN  occludin 
 P4HB  prolyl 4-hydroxylase, beta polypeptide 
 PEBP1  phosphatidylethanolamine binding protein 1 
 PLAT  plasminogen activator, tissue 
 PLG  plasminogen 
 POSTN  periostin, osteoblast specific factor 
 PRDX4  peroxiredoxin 4 
 PRELP  proline/arginine-rich end leucine-rich repeat protein 
 PRSS1  protease, serine, 1 (trypsin 1) 
 PRSS3  protease, serine, 1 (trypsin 1) 
 PTPRC  protein tyrosine phosphatase, receptor type, C 
 RPL22  ribosomal protein L22 
 SERPINA3  serpin peptidase inhibitor, clade A, member 3 
 SERPINA5  serpin peptidase inhibitor, clade A, member 5 
 SERPINC1  serpin peptidase inhibitor, clade C (antithrombin), member 1 
 SERPINE1  serpin peptidase inhibitor, clade E, member 1 
 SFRP1  secreted frizzled-related protein 1 
 SLC39A4  solute carrier family 39 (zinc transporter), member 4 
 SLPI  secretory leukocyte peptidase inhibitor 
 SNCA  synuclein, alpha (non A4 component of amyloid precursor) 
 SOD1  superoxide dismutase 1, soluble 
 SOD3  superoxide dismutase 3, extracellular 
 TF  transferrin 
 THBS1  thrombospondin 1 
 THBS2  thrombospondin 2 
 THBS4  thrombospondin 4 
 TNC  tenascin C 
 TNXB  tenascin XB 
 TPSAB1/TPSB2  tryptase alpha/beta 1 
 TTR  transthyretin 
 TXN  thioredoxin 
 VTN 
 Vitronectin 
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Supplementary Table 4: List of HBPs associated with PDAC 
 
Symbol Entrez Gene Name 
  
 A2M  alpha-2-macroglobulin 
 ABP1  amiloride binding protein 1 (amine oxidase (copper-containing)) 
 ADAMTS1  ADAM metallopeptidase with thrombospondin type 1 motif, 1 
 AGT  angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 
 ANXA1  annexin A1 
 ANXA2  annexin A2 
 ANXA5  annexin A5 
 APOE  apolipoprotein E 
 APP  amyloid beta (A4) precursor protein 
 AQP1  aquaporin 1 (Colton blood group) 
 ARG1  arginase, liver 
 ATP1B3  ATPase, Na+/K+ transporting, beta 3 polypeptide 
 ATP2B1  ATPase, Ca++ transporting, plasma membrane 1 
 ATP5A1  ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1 
 B2M  beta-2-microglobulin 
 BACE1  beta-site APP-cleaving enzyme 1 
 BGN  biglycan 
 C3  complement component 3 
 C6  complement component 6 
 C9  complement component 9 
 CCL19  chemokine (C-C motif) ligand 19 
 CCL21  chemokine (C-C motif) ligand 21 
 CCL24  chemokine (C-C motif) ligand 24 
 CD36  CD36 molecule (thrombospondin receptor) 
 CD47  CD47 molecule 
 CEL  carboxyl ester lipase (bile salt-stimulated lipase) 
 CFH  complement factor H 
 CLU  clusterin 
 COL11A1  collagen, type XI, alpha 1 
 COL12A1  collagen, type XII, alpha 1 
 COL1A1  collagen, type I, alpha 1 
 COL1A2  collagen, type I, alpha 2 
 COL2A1  collagen, type II, alpha 1 
 COL3A1  collagen, type III, alpha 1 
 COL4A1  collagen, type IV, alpha 1 
 COL4A2  collagen, type IV, alpha 2 
 COL5A1  collagen, type V, alpha 1 
 COL6A3  collagen, type VI, alpha 3 
 COMP  cartilage oligomeric matrix protein 
 CP  ceruloplasmin (ferroxidase) 
 CTSG  cathepsin G 
 CX3CL1  chemokine (C-X3-C motif) ligand 1 
 CXCL2  chemokine (C-X-C motif) ligand 2 
 CXCL12  chemokine (C-X-C motif) ligand 12 
 CYCS  cytochrome c, somatic 
 DCC  deleted in colorectal carcinoma 
 ECE1  endothelin converting enzyme 1 
 EFNA1  ephrin-A1 
 ENO1  enolase 1, (alpha) 
 ENPP1  ectonucleotide pyrophosphatase/phosphodiesterase 1 
 F2  coagulation factor II (thrombin) 
 F10  coagulation factor X 
 F11  coagulation factor XI 
 FBN1  fibrillin 1 
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 FGA  fibrinogen alpha chain 
 FGB  fibrinogen beta chain 
 FGF3  fibroblast growth factor 3 
 FGF5  fibroblast growth factor 5 
 FGFR2  fibroblast growth factor receptor 2 
 FGG  fibrinogen gamma chain 
 FLT1  fms-related tyrosine kinase 1  
 FN1  fibronectin 1 
 FST  follistatin 
 FSTL1  follistatin-like 1 
 GJB1  gap junction protein, beta 1, 32kDa 
 GPNMB  glycoprotein (transmembrane) nmb 
 GSN  gelsolin 
 HBEGF  heparin-binding EGF-like growth factor 
 HDGF  hepatoma-derived growth factor 
 HMGB1  high-mobility group box 1 
 HSPG2  heparan sulfate proteoglycan 2 
 IGFBP2  insulin-like growth factor binding protein 2, 36kDa 
 IGFBP3  insulin-like growth factor binding protein 3 
 IGFBP5  insulin-like growth factor binding protein 5 
 IGFBP6  insulin-like growth factor binding protein 6 
 IHH  Indian hedgehog 
 IL3  interleukin 3 (colony-stimulating factor, multiple) 
 IL8  interleukin 8 
 IL10  interleukin 10 
 INHBA  inhibin, beta A 
 ITGA1  integrin, alpha 1 
 ITGA5  integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
 ITGAV  integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) 
 ITGB1  integrin, beta 1  
 ITGB3  integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 
 KAL1  Kallmann syndrome 1 sequence 
 LAMA2  laminin, alpha 2 
 LAMA3  laminin, alpha 3 
 LAMC2  laminin, gamma 2 
 LTBP1  latent transforming growth factor beta binding protein 1 
 MDK  midkine (neurite growth-promoting factor 2) 
 MET  met proto-oncogene (hepatocyte growth factor receptor) 
 MMP2  matrix metallopeptidase 2  
 MMP7  matrix metallopeptidase 7 (matrilysin, uterine) 
 MMP9  matrix metallopeptidase 9  
 MMP14  matrix metallopeptidase 14 (membrane-inserted) 
 MYL9  myosin, light chain 9, regulatory 
 NAV2  neuron navigator 2 
 NT5E  5'-nucleotidase, ecto (CD73) 
 OCLN  occludin 
 P4HB  prolyl 4-hydroxylase, beta polypeptide 
 PCSK6  proprotein convertase subtilisin/kexin type 6 
 PEBP1  phosphatidylethanolamine binding protein 1 
 PLAT  plasminogen activator, tissue 
 PLAU  plasminogen activator, urokinase 
 POSTN  periostin, osteoblast specific factor 
 PRDX4  peroxiredoxin 4 
 PRELP  proline/arginine-rich end leucine-rich repeat protein 
 PRSS1  protease, serine, 1 (trypsin 1) 
 PRSS3  protease, serine, 1 (trypsin 1) 
 PTPRC  protein tyrosine phosphatase, receptor type, C 
 RPL22  ribosomal protein L22 
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 SEMA5A  semaphorin 5A 
 SERPINA1  serpin peptidase inhibitor, clade A, member 1 
 SERPINA3  serpin peptidase inhibitor, clade A, member 3 
 SERPINA5  serpin peptidase inhibitor, clade A, member 5 
 SERPINA6  serpin peptidase inhibitor, clade A, member 6 
 SERPINE1  serpin peptidase inhibitor, clade E, member 1 
 SERPINE2  serpin peptidase inhibitor, clade E, member 2 
 SERPING1  serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 
 SFRP1  secreted frizzled-related protein 1 
 SLC2A2  solute carrier family 2 (facilitated glucose transporter), member 2 
 SLC39A4  solute carrier family 39 (zinc transporter), member 4 
 SLC3A2  solute carrier family 3, member 2 
 SLC4A4  solute carrier family 4, sodium bicarbonate cotransporter, member 4 
 SLPI  secretory leukocyte peptidase inhibitor 
 SNCA  synuclein, alpha (non A4 component of amyloid precursor) 
 SOD1  superoxide dismutase 1, soluble 
 STEAP4  STEAP family member 4 
 SYNGR1  synaptogyrin 1 
 TF  transferrin 
 TGM2 transglutaminase 2  
 THBS1  thrombospondin 1 
 THBS2  thrombospondin 2 
 THBS4  thrombospondin 4 
 TNC  tenascin C 
 TNFAIP6  tumor necrosis factor, alpha-induced protein 6 
 TNXB  tenascin XB 
 TTR  transthyretin 
 VEGFB  vascular endothelial growth factor B 
 VTN  vitronectin 
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2.5 Drug targets in pancreatic diseases 
Pubmatrix, which is a literature-mining tool (Becker et al., 2003), was used 
to assign functional relevance to HBPs in the major pancreatic diseases. Lists 
of HBPs, identified for further investigation, along with MeSH (Medical 
Subject Headings) such as “drugs” and “drugs in acute pancreatitis” were 
searched in Pubmatrix (Table 2.5.1). The search revealed that a number of 
the HBPs have been investigated in drug development in AP, some of which 
have been listed (Table 2.5.2). Similar searches were carried out in CP and 
PDAC, using Pubmatrix. FGFR2, which was identified as a potential PSC-
specific drug target in PDAC in the in silico study described Section 2.3 of 
this chapter, is being investigated in the treatment of other cancers (Byron 
and Pollock, 2009).  
 
HBPs Drugs Drugs in acute pancreatitis 
APOA5 14 0 
CCL2 517 0 
CXCL10 122 0 
IFNγ 254 0 
IL6 288 1 
IL10 1040 16 
LIPC 10 0 
LPL 231 2 
MBL 84 0 
MPO 689 10 
PDGFβ 2 0 
PON1 92 0 
PROC 9396 1 
SELP 25 0 
TGFβ1 119 1 
TNF 9601 37 
VEGFA 537 0 
 
Table 2.5.1: HBPs as potential drug targets in acute pancreatitis. The literature-
mining tool “Pubmatrix” was searched using HBPs shortlisted as potential drug 
targets and MeSH terms “drugs” and “drugs in acute pancreatitis”. 
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A number of drugs against FGFR2 (Table 2.5.3) are in various stages of 
investigation. The top canonical pathways (Fig. 2.5) were also used to 
identify potential pathway-specific drug targets.  
 
HBPs Drugs in acute pancreatitis 
IL10 FTY720, Emblica offiinalis 
LPL Alipogene tiparvovec 
MPO Ethyl pyruvate, Ligustrazine 
TGFβ1 Emodin and Sandostatin 
TNF ND-07, Flavocoxid 
 
Table 2.5.2: Drugs against HBPs in acute pancreatitis. A number of drugs 
against HBPs have been investigated in acute pancreatitis. 
 
Drugs against FGFR2 Cancers 
TKI-258 
Gastrointestinal Stromal 
tumour 
AZD2171 
Renal cell carcinoma, 
breast cancer 
BIFB-1120 
Non-small cell lung 
cancer 
Brivanib Metastatic solid tumours 
 
Table 2.5.3: Drugs against FGFR2 in the treatment of cancer. A number of 
drugs against FGFR2 are being investigated in clinical trials in various cancers. 
FGFR2 has been identified as potential drug target against pancreatic stellate 
cells in the treatment of pancreatic ductal adenocarcinoma. 
 
2.6 Discussion 
This work addressed the hypothesis that the high level of connectivity of 
HBPs discovered on a genome-wide basis would also be true at the level of 
an organ (Chapter 1; 1.9).  It showed that HBPs constitute an important 
extracellular sub-proteome within the pancreas and is likely to provide a 
rich repository of potential biomarkers and drug targets. However, it is 
based on two assumptions.  The first is that the current list of HBPs (Ori et 
al., 2011) is reasonably comprehensive.  The latter study used a combination  
 Figure 2.5: Top canonical pathway in AP. ‘Hepatic Fibrosis / Hepatic Stellate Cell Activation’ canonical pathway (CP) was the top canonical pathway 
enriched to the AP HBP dataset, using Ingenuity Pathways Analysis. The nodes outlined in magenta are HBPs from the AP dataset. The top cluster in the AP 
HBP dataset enriches to this pathway.  
of literature curation and affinity mass spectrometry of HBPs derived from 
rat liver.  There is no indication of the depth of the affinity proteomics, that 
is how sensitive the measurements were and so how comprehensive they 
might be.  Moreover, one might expect differences between liver and 
pancreas, since they have different endocrine and exocrine functions. In 
addition, there has, as yet, been no follow up investigations in rat liver (the 
tissue used as a source of HBPs) or other tissues to determine how 
comprehensive the list actually is.  The second assumption is that mRNA is 
reasonably representative of protein.  It is established that the correlation is 
not that strong. For example, translation efficiency can vary considerably 
between mRNAs (Schwanhausser et al., 2011), and the methods used to 
measure mRNA levels can reduce the correlation further (Mournetas et al., 
2014).  The need to perform a meta analysis across different experimental 
measurements of mRNA, discussed in Section 2.3, may reduce further such 
correlation,   
Thus, while the analysis of HBPs in pancreatic diseases supports the 
hypothesis that HBPs may provide the key to understanding how cell 
communication is altered in disease, the evidence is indirect. Heparin 
binding, which defines the regulatory importance of HBPs, may be exploited 
by a direct proteomic approach using heparin-affinity chromatography on 
tissue or a body fluid. This approach, first used in (Ori et al., 2011), will be 
used in Chapter 3 to identify HBPs in the normal mouse pancreas and in a 
mouse model of AP.  This approach will test directly the hypothesis that 
HBPs are central to one pancreatic disease.  It will also determine the extent 
to which the above assumptions hold.  The systems biology approach 
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outlined in Section 2.2 and applied in Section 2.3 will provide the means to 
analyse the data. 
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Chapter 3 – Heparin binding proteins in NP and AP 
 
3.1 Introduction 
Individual studies have demonstrated a variety of mechanisms whereby 
binding to HS regulates the function of extracellular proteins. However, only 
recently has it been demonstrated on a global scale that, of the extracellular 
proteins, HBPs form a highly interconnected network that is functionally 
linked to physiological and pathological process in more complex 
multicellular organisms (Ori et al., 2011). Importantly from the perspective 
of pancreatic diseases, HBPs, because they bind to heparin and are 
extracellular, represent easily accessible new targets for the development of 
biomarkers and drugs. We have shown that HBPs are indeed a key subclass 
of extracellular proteins, whose pattern of expression differs in the healthy 
and diseased pancreas (Chapter 3 and (Nunes et al., 2013)). However, this 
work has important weaknesses. mRNA expression was by necessity used as 
a proxy for that of protein, but this is known to not always be the case 
(Schwanhausser et al., 2013, Li et al., 2014). Therefore, a proteomic analysis 
of HBPs in normal mouse pancreas and in the caerulein-induced mouse 
model of acute pancreatitis was undertaken, with the aim of identifying 
HBPs.  This would, therefore, allow the hypothesis elaborated in Section 1.9, 
that HBPs form highly connected regulatory modules in the cell 
microenvironment and are an important source of potential new 
biomarkers and drug targets in pancreatic diseases to be tested directly. 
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The proteomics analysis will be submitted as a manuscript to the Journal of 
Biological Chemistry (3.5), which describes the bulk of the data.  The mass 
spectrometry proteomics data has been uploaded into PRIDE database 
(http://www.ebi.ac.uk/pride/archive/)(Vizcaino et al., 2013), via its 
partner repository, the ProteomeXchange Consortium (Vizcaino et al., 
2014), with the dataset identifier PXD001950. Additional information 
relating to methods are provided in Sections 3.2-3.4) and further discussion 
in Section 3.6). 
 
3.2 Methodology 
Studies were conducted in compliance with UK Home Office regulations, and 
with the Institutional ethical review processes of the University of Liverpool. 
The isolation of plasma membrane was performed as in Ori et al., 2011 (Ori 
et al., 2011) The workflow to isolate and detect the plasma membrane 
fraction is depicted below (Fig. 3.1). Pancreases were obtained from 6-8 
week old male adult CD1 mice (weight range, 24-30 g) with normal 
pancreas (NP) or experimental acute pancreatitis (AP). The pancreatic 
tissue was homogenized and then subjected to sequential steps of 
centrifugation to obtain the various subcellular fractions. The supernatant 
obtained after removal of the nuclear, mitochondrial and cytosolic fractions 
was subjected to ultracentrifugation to obtain a microsomal pellet, which 
contained ER membranes and plasma membranes. This was then subjected 
to differential ultracentrifugation on a sucrose gradient. The fractions with 
the highest caveolin-1 signal intensity on Western Blot, using a polyclonal 
 84 
antibody against caveolin-1, were pooled together to obtain the plasma 
membrane fraction. This was then subjected to heparin chromatography to 
obtain the heparin-bound fraction, which was prepared for mass 
spectrometry (MS). Detailed description of isolation of the plasma 
membrane fraction, the sample preparation for MS and the MS analysis are 
outlined in the manuscript attached later in this chapter (3.5). 
 
                          
 
Figure 3.1: A schematic representation of the various steps involved in extracting 
HBPs from mouse pancreases 
 
TISSUE HOMOGENISATION 
SUB-CELLULAR FRACTIONATION 
MICROSOMAL FRACTIONATION 
PLASMA MEMBRANE 
FRACTION 
SUCROSE GRADIENT SEPARATION 
HEPARIN CHROMATOGRAPHY 
PREPARATION OF MS SAMPLES 
HPLC/MASS SPECTROMETRY 
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3.2.1 Method modifications  
Some of the modifications to the methods described by Ori et al., 2011 
(reference) are described in the sections that follow. 
3.2.1.1 Measurement of protein concentration 
The BCA (bicinhoninic acid) assay (Pierce™ BCA Protein Assay Kit, Thermo 
Fisher Scientific, U.K.) was used instead of the Bradford assay to measure 
protein concentration at all steps, as it was compatible with most detergents 
including Triton-X-100. 
3.2.1.2 Heparin affinity chromatography 
Isolation of HBPs using heparin affinity chromatography and their 
separation into 3 fractions depending on their affinity was attempted using 
a reverse step gradient on a heparin column, as described by Ori et al., 2011 
(reference). In order to preserve precious samples of pancreas, lung tissue 
from mice with caerulein induce acute pancreatitis was used. The high 
affinity fraction (H) was obtained by adjusting the resuspended pellets to 
0.6 M NaCl and 1 % (v/v) Triton X-100 and centrifuged for 5 min at 4,000 x 
g to remove any insoluble material. The supernatant was applied to a 1 ml 
Hi-Trap heparin column (GE Healthcare Life Sciences) equilibrated with 
buffer WH (0.6 M NaCl, 13.7 mM Na2HPO4, 6.3 mM NaH2PO4, 0.1 % (v/v) 
Triton X-100, pH 7.2). After loading, the column was extensively washed 
with buffer WH until the absorbance at 280 nm reached the baseline. Bound 
proteins (fraction H) were then eluted with a one column volume of buffer E 
(2 M NaCl, 13.7 mM Na2HPO4, 6.3 mM NaH2PO4, 0.1 % (v/v) Triton X-100, 
pH 7.2). The unbound fraction from the 0.6 M NaCl load and wash was then 
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diluted to 0.4 M NaCl using phosphate buffer (13.7 mM Na2HPO4, 6.3 mM 
NaH2PO4, pH 7.2) and reapplied to the heparin column equilibrated in buffer 
WM (0.4 M NaCl, 13.7 mM Na2HPO4, 6.3 mM NaH2PO4, 0.1 % (v/v) Triton X-
100, pH 7.2). After extensive washing with buffer WM, the medium affinity 
fraction (M) was eluted with 2 M NaCl, as described above.  
 
 
 
Figure 3.2.1: Silver stained SDS-PAGE gels of the high affinity (H), medium 
affinity (M) and low affinity (L) heparin-bound plasma membrane fractions. 
Lung tissue from mice with caerulein-induce acute pancreatitis was used in the 
above experiments. 
 
The unbound fraction following elution of M was diluted to 0.15 M NaCl in 
the same phosphate buffer, reapplied to the heparin column equilibrated in 
buffer WL (0.15 M NaCl, 13.7 mM Na2HPO4, 6.3 mM NaH2PO4, 0.1 % (v/v) 
Triton X-100, pH 7.2) and eluted (fraction L) after extensive washing, as 
above. The SDS-PAGE gels stained with silver nitrate (Fig. 3.2.1) showed that 
the low affinity fraction using buffer WL included bands present in the other 
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fractions.  Though the identity of these polypeptides was not established, 
this is consistent with what was observed previously, that is the three 
fractions contain very substantially overlapping proteins (Ori et al 2011). 
Thus, little information is gained by producing fractions eluted with  
 
A       B 
Figure 3.2.2: Coomassie stained SDS-PAGE gels of various fractions (Str1, Str2, 
Str3) of cytosolic proteins from pancreatic tissue post-adsorption using 
StrataClean Resin
TM
 with  (A) and without 0.1% (v/v) Triton X-100 (B). The 
experiment showed that Triton X-100 was affecting the adsorption of protein 
onto the StrataClean Resin. 
 
different concentrations of NaCl, while such a procedure will reduce the 
amount of protein in each fraction. Hence a single buffer (WL) was used to 
isolate the heparin bound fraction from the pancreas, so as to increase the 
amount of protein for analysis. 
250 
50 
25 
15 
10 
kDa 
Str1 Str2 Str3 Str1 Str2 Str3 0 0 
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3.2.1.3 Processing of the heparin-bound plasma membrane fraction 
Triton-X-100 is a very effective detergent for solubilising membranes, but it 
is polydisperse and not compatible with mass spectrometry. StrataClean 
Resin (Stratagene, Hycor Biomedical Ltd., Edinburgh, U.K.) was investigated 
as a means to process the heparin-bound plasma membrane fraction and 
remove Triton-X-100. The maximum binding capacity of 10 μL of 
StrataClean resin is reported to be 100 μg of protein by the manufacturer. 
Ten μL of premixed StrataClean resin was added to 1 ml of protein solution.  
This was then vortexed for 1 minute. The protein-bound StrataClean resin 
(Str1) was collected by centrifugation at 2000 rpm for 1 minute. The 
supernatant (S1) was removed and stored. To the pelleted protein-resin 
mixture, 10 µL of 2X SDS-PAGE  
  
Figure 3.2.3: Coomassie stained SDS-PAGE gels of various fractions (Str1, Str2, 
Str3) of whole cell lysate from pancreatic tissue post-adsorption using 
StrataClean Resin
TM
 with 0.1% (v/v) Triton X-100. The experiment showed that 
Triton X-100 was affecting the adsorption of protein onto the StrataClean Resin. 
250 
50 
25 
15 
10 
kDa 
Str1 Str2 Str3 0 
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protein-loading buffer was added and this was applied onto an SDS-PAGE 
gel. The supernatant (S1) was processed as above to obtain Str2. Similarly 
the supernatant from processing Str2 was processed to obtain Str3. 
Adsorption using samples of protein with and without 0.1% (v/v) Triton X-
100 was investigated (Fig. 3.2.2). Whole cell lysate (Fig.3.2.3) and heparin-
bound plasma membrane fractions (Fig.3.2.4) were also used to investigate 
the use of StrataClean. 
 
Figure 3.2.4: Silver nitrate stained SDS-PAGE gels of various fractions (Str1, 
Str2, Str3) of heparin-bound plasma membrane fraction from pancreatic tissue 
post-adsorption using StrataClean Resin
TM
 with 0.1% (/v) Triton X-100. The 
experiment showed that Triton X-100 was affecting the adsorption of protein 
onto the StrataClean Resin. 
 
Since Triton-X-100 was found to interfere with protein binding to 
Strataclean resin and so causing loss of sample, TCA precipitation was 
250 
50 
25 
15 
10 
kDa 
Str1 Str2 Str3 0 
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investigated as an alternative. This was found to be satisfactory for 
processing the samples post-heparin affinity chromatography (Fig. 3.2.5).  
To avoid wasting experimental samples the correlation of pellet size post-
TCA precipitation was done using BSA (Bovine Serum Albumin, Sigma 
Aldrich UK). Varying concentrations of BSA were precipitated using TCA as 
described earlier. The pellets were then washed 5 times with 5% (w/v) TCA 
and freeze-dried overnight. They were then washed with diethyl ether to 
remove the excess TCA and centrifuged at 5000 rpm. The supernatant was 
removed and the diethyl ether wash was repeated 2 more times. The final 
pellets were then left to dry in the fume hood.  
 
Figure 3.2.5: Silver nitrate stained SDS-PAGE gels of the heparin-bound plasma 
membrane fraction from pancreas in 0.1% (v/v) Triton X-100 post-TCA 
precipitation and post-adsorption using StrataClean Resin
TM
. The experiment 
showed that TCA precipitation was more effective in processing the samples as 
compared to StrataClean Resin
 
(Str1 and Str2). 
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The pellets were then stained with Coomasie Blue (Fig. 3.2.6) to obtain a 
visual correlation between pellet size and protein concentration. 
             
Figure 3.2.6: Coomasie Blue stained pellets of BSA post-TCA precipitation. This 
experiment provides an approximate correlation between protein concentration 
and size of the pellet. 
 
3.3 Bioinformatics pipeline 
Extracellular proteins were identified using a combination of bioinformatics 
tools, in order to achieve the widest and most accurate coverage. SignalP 4.1, 
which predicts the presence of a secretory signal peptide, was used to 
identify extracellular proteins (Petersen et al., 2011) with Phobius, which is 
a combined transmembrane topology and signal peptide prediction tool, to 
obtain a wider coverage for extracellular protein identification (Kall et al., 
2007).  
A third tool, namely, SecretomeP 2.0, which produces ab initio predictions of 
protein secretion not based on a secretory signal peptide (Bendtsen et al., 
2004) and a fourth tool based on ontology, Ingenuity Pathways Analysis 
(IPA), was used to identify extracellular and plasma membrane proteins. 
The HBPs that were not identified using SignalP, Phobius, or SecretomeP, 
but which were identified using IPA were further investigated using a 
manual approach. Each candidate HBP was examined using UniProtKB for 
0.5μg 1 μg 20 μg 10 μg 
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the presence of an extracellular signature. A search in Pubmed, using the 
terms “extracellular” or “secreted” was performed to investigate those 
proteins that still had an ambiguous subcellular location to identify at least 
one publication demonstrating an unequivocal plasma membrane and or 
extracellular localisation. Finally, the outputs of the various approaches 
were merged to obtain the final list of HBPs in NP and AP. 
 
 
Figure 3.3: Bioinformatics pipeline used to identify HBPs (Ec =extracellular). A 
combination of various bioinformatics tools and manual curation was used to 
identify HBPs. 
SignalP Phobius SecretomeP 
Ec HBPs 
Ingenuity 
Ontology 
Ec signature 
(UniProt KB) 
PubMed Ambigious location 
Ingenuity Ec 
+ 
+ + + 
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3.4 Identification of potential biomarkers and drug targets in AP 
Label-free quantification was performed following the “Top3” methodology 
(Silva et al., 2006) by spiking the sample prior to analysis with an internal 
standard of 50 fmol yeast alcohol dehydrogenase digest (Uniprot P00330, 
Waters). Proteins were annotated as differentially expressed if they 
achieved a FDR corrected q value of 1%. The Bonferroni correction was 
used to increase the stringency and further reduce the number of false 
positives for the purpose of biomarker identification (Ting et al., 2009). 
Canonical pathways and cluster analysis were used in conjunction with 
differential expression as tools to identify potential functional biomarkers 
and drug targets. 
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3.5.1 Capsule  
Background: Extracellular heparin-binding proteins (HBPs) are key 
regulators of cell communication.  
Results: HBPs in normal mouse pancreas (NP) and in a mouse model of 
acute pancreatitis (AP), including 460 new ones, were identified.  
Conclusion: The HBPs form highly interconnected protein-protein 
interaction networks describing cell communication pathways in NP and in 
AP. 
Significance: HBPs are a source of potential biomarkers and of drug targets 
in AP and are accessible by virtue of their extracellular location and 
heparin binding property.  
 
3.5.2 Abstract  
Acute pancreatitis (AP) is an acute inflammation of the pancreas, 
mainly caused by gallstones and alcohol, and driven by changes in 
communication between cells. Heparin-binding proteins (HBPs) of the 
plasma membrane and extracellular matrix play a central role in cell 
communication. Therefore, we used heparin affinity proteomics to 
identify the extracellular HBPs in mouse normal pancreas (NP) and in 
a caerulein mouse model of AP. Many new HBPs (460) were 
discovered more than doubling their total number to 883. A number 
of the new HBPs are proteins with well-characterised intracellular 
functions, e.g. NDUFS4, NDUFS6, but which also have a documented 
extracellular presence with potential ‘moonlighting’ roles. The HBPs 
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form highly interconnected protein-protein interaction networks in 
both NP and AP, as well as globally. Thus, HBPs may represent the 
most interconnected set of extracellular proteins and so those with 
the greatest regulatory potential. HBPs in NP are associated with 
biological functions such as molecular transport, cellular movement 
and tissue architecture that underlie pancreatic homeostasis.  
However, in AP HBPs are additionally associated with processes such 
as acute phase response signalling, complement system and 
mitochondrial dysfunction. By virtue of their extracellular location 
and heparin binding property, HBPs are easily accessible and are 
potential biomarkers and drug targets in AP.  
 
3.5.3 Introduction 
The pancreas develops from endodermal cells in the foregut and has 
important exocrine and endocrine functions (Zaret and Grompe, 2008). 
Acute pancreatitis (AP) is acute inflammation of the pancreas and is mainly 
caused by gallstones and alcohol (Pandol et al., 2007). It is the leading 
cause for hospitalization in the United States and has significant quality of 
life implications for the patient and cost implications health systems (Wu 
and Banks, 2013). Although most episodes of AP are mild and self-limiting, 
the severe form of the disease, accompanied by a systemic inflammatory 
response syndrome and multi-organ failure, is associated with a high 
mortality. At a cellular level disruption in calcium homeostasis and 
signaling, and mitochondrial dysfunction have been implicated in the 
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pathogenesis of AP (Gerasimenko et al., 2014, Mukherjee et al., 2008). The 
clinical characteristics of AP suggest that an important molecular 
component is change in cell communication within the pancreas and, in 
severe AP, systemically between the pancreas and other organs.  Cell 
communication occurs through the medium of the extracellular matrix, 
with cell receptors responsible for generating the cellular response. 
The importance of extracellular proteins in mediating communication 
between cells in multicellular organisms is underscored by the 
demonstration that the increase in complexity of multicellular organisms is 
accompanied by an expansion and increase in complexity of extracellular 
proteins and their complexity (Vogel and Chothia, 2006). A key non-protein 
component of the extracellular space is the glycosaminoglycan heparan 
sulfate (HS), because it binds and regulates the activity of a large number of 
extracellular proteins involved in cell communication (Xu and Esko, 2014, 
Ori et al., 2008). HS is formed of linear repeats of a characteristic 
disaccharide of 1,4 linked uronic acid (-L-iduronate, IdoA, or -D-
glucuronate, GlcA) and -D-glucosamine  (GlcN), with variable O-sulfation 
of C2 on the uronic acid, of C3 and C6 on the glucosamine; the glucosamine 
being either N-acetylated or N-sulfated (Xu and Esko, 2014, Ori et al., 
2008). These modifications are hierarchical (Xu and Esko, 2014), resulting 
in chains with a distinct domain structure (Murphy et al., 2004); HBPs bind 
to the sulfated domains and their flanking transition domains. HS chains 
are attached to proteins to form proteoglycans (HSPGs), with the core 
proteins serving in part to direct chains to particular extracellular locations 
(Uniewicz et al., 2012, Xu and Esko, 2014) Heparin is often used as a proxy 
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for the sulfated domains of HS, though it is more homogenous and sulfated 
than these (Ori et al., 2008, Xu and Esko, 2014).  
Many individual studies have demonstrated a variety of mechanisms 
whereby binding to HS regulates the function of extracellular proteins, but 
only recently has this been analysed on a global scale (Ori et al., 2011). This 
work demonstrated that of the extracellular proteins, the HBPs form a 
highly interconnected functional network through protein-protein 
interactions that are functionally linked to physiological and pathological 
process in more complex multicellular organisms.  This and other work 
identify HBPs as important signalling molecules in the cellular 
microenvironment that influence fundamental biological processes in 
development, homeostasis and disease (Ori et al., 2011, Malavaki et al., 
2011, Xu and Esko, 2014).  
We previously used mRNA expression data as a proxy for protein, to test 
the hypothesis that HBPs, which are demonstrably functionally important 
at a genome-wide level (Ori et al., 2011), are equally important in the 
context of a single organ, the pancreas, and its associated digestive diseases 
(Nunes et al., 2013). This work showed that HBPs are indeed a key subclass 
of extracellular proteins, whose pattern of expression differs in the healthy 
and diseased pancreas. Importantly from the perspective of pancreatic 
diseases, HBPs, because they bind to heparin and are extracellular, 
represent easily accessible new targets for the development of biomarkers 
and drugs.  However, this work has important weaknesses.  mRNA 
expression was by necessity used as a proxy for that of protein, but this is 
known to not always be the case (Schwanhausser et al., 2013, Li et al., 
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2014).  Moreover, the use of mRNA assumes that the existing set of 435 
HBPs (Ori et al., 2011) is reasonably representative of those expressed in 
pancreas and that this organ does not express substantial, novel HBPs. 
We have, therefore, undertaken a proteomic analysis of HBPs in normal 
mouse pancreas and in the caerulein-induced mouse model of acute 
pancreatitis. A large number of HBPs were identified, more than doubling 
their number to 883. These HBPs are highly interconnected in NP, AP and 
globally. They may represent the most interconnected set of extracellular 
proteins, and, therefore, those with the greatest regulatory potential. Non-
canonical extracellular HBPs such as NDUFS4, NDUFS6, NDUFS7, NDUFS8, 
NDUFA9 and NDUFA10 were found to be under-expressed in AP compared 
to NP, using label-free quantification. These may have potential 
moonlighting roles not previously known. HBPs are functionally important 
in NP and AP and being accessible, by virtue of their extracellular location 
and heparin binding property, are potential biomarkers and drug targets in 
AP.  
  
3.5.4 Experimental procedures 
3.5.4.1 Pancreatic murine models  
CD1 mice were used in all experiments as they are genetically 
heterogeneous and more likely to represent the human population 
(Festing, 2010). Pancreases were obtained from 6-8 week old male adult 
CD1 mice (weight range, 24-30 g) with normal pancreas (NP) or 
experimental acute pancreatitis (AP). In order to induce experimental acute 
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pancreatitis, CD1 mice were fasted for 12 hours before each experiment, 
following which they were administered seven hourly intraperitoneal 
injections of caerulein (50 µg /kg; Sigma Chemical Co., St. Louis, MO) 
dissolved in 0.9% (w/v) saline (Braun Medical Ltd., Aylesbury, England). 
Pancreatitis was confirmed in the experimental mice 24 hours after the 
first intraperitoneal injection. All mice (NP and AP) were euthanized by 
cervical dislocation. Studies were conducted in compliance with UK Home 
Office regulations, and with the Institutional ethical review processes of the 
University of Liverpool.  
A blood sample was collected for serum amylase determination. Serum 
amylase was tested in the Clinical Biochemistry Department in Royal 
Liverpool University Hospital using a kinetic method. A sliver of pancreatic 
tissue from each of the pancreases was fixed in formalin for H&E staining 
and histological examination. The pancreases were removed, weighed, 
pooled together and stored in buffer H (10 mM HEPES pH 7.5, 5 mM MgCl2, 
25 mM KCl, 0.25 M sucrose supplemented with CompleteTM protease 
inhibitors cocktail, Roche Products Ltd, Welwyn Garden City, UK) at 4°C. 
CompleteTM protease inhibitor was used in all experiments as it has been 
shown to be particularly effective in experiments involving pancreatic 
tissue (Wandschneider et al., 2001). Sixteen CD1 mice were used for each 
HBP isolation experiment. Each experiment was performed thrice for NP 
and AP. 
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3.5.4.2 Isolation of a plasma membrane enriched fraction  
The isolation of the plasma membrane from murine pancreases was 
performed as in Ori et al., 2011, with a few minor modifications (Ori et al., 
2011). All the steps were performed on ice or at 4°C. Briefly, mouse 
pancreases were minced and homogenised with buffer H using a 30 mL 
Potter-Elvehjem homogeniser (30-40 strokes). Subcellular fractionation 
was performed using sequential steps of centrifugation. The homogenate 
was centrifuged for 20 min at 1,000 g in a Sorvall centrifuge (SS-34 rotor) 
(DuPont UK, Stevenage, UK). The pellet was resuspended with buffer H, 
homogenised and centrifuged at the same speed. The two supernatants 
were then combined (S1) and centrifuged for 20 min at 25,000 g. This 
supernatant was transferred to a fresh tube and the centrifugation 
repeated. The final supernatant (S2) was centrifuged for 45 min at 135,000 
g in a Sorvall Ultra Pro 80 ultracentrifuge (T.865.1 rotor) to produce a 
microsomal pellet, which was washed with 8 ml of buffer H (W) by 
resuspension and centrifuged as above. 
The final microsomal pellet was resuspended by homogenisation in a 
Dounce homogeniser (5 mL) with 4 mL of 1.55 M sucrose in buffer H and 
placed on a 2 mL 2 M sucrose cushion in a swing-bucket ultracentrifuge 
tube.  It was then overlaid with 2.5 mL 1.33 M, 2 mL 1.2 M, 2 mL 1.1 M, 1 
mL 0.77 M and 1 mL 0.25 M sucrose all in buffer H. The sucrose gradient 
was centrifuged for 16 h at 116,000 g in a Sorvall Ultra Pro 80 
ultracentrifuge (AH-629 rotor). Purdenz™ (GENTAUR Belgium BVBA) was 
pumped into the bottom of the tube using a 20 mL syringe to collect 1 mL 
fractions (F1-F12) from the top of the sucrose gradient. The first eleven 
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fractions  (F1-F11) were diluted eight times with buffer H and centrifuged 
for 45 min at 135,000 g. The last fraction was discarded. The pellets thus 
obtained (P2-P11) were resuspended with 400 μL 2 % (v/v) Triton X-100 
(Sigma Aldrich) in phosphate-buffered saline (PBS; 10 mM Na2HPO4, 1.8 
mM KH2PO4, 137 mM NaCl and 2.7 mM KCL, pH 7.4) using a Dounce 
homogeniser (1 mL). Protein concentration was measured by the 
bicinchoninic acid (BCA) protein assay (Pierce, Thermo Fisher Scientific, 
Northumberland, UK) in 1:20 dilutions of the resuspended pellets (final 
Triton X-100 concentration: 0.1 % (v/v)). Equal amounts of the 
resuspended pellets P1-P11 were analysed by SDS-PAGE and by western 
blot, using a polyclonal antibody to caveolin1 (sc-890, Santa Cruz 
Biotechnology Inc., Insight Biotechnology, Wembley, UK). After gel 
electrophoresis, samples were transferred to HybondTM nitrocellulose 
membrane (GE Healthcare Life Sciences) using a wet system (Mini Trans-
Blot Cell, Bio-Rad Laboratories Ltd) for 1 h at 100 V. Membranes were 
blocked with TBS (20 mM Tris-HCl, 150 mM NaCl, pH 7.5) supplemented 
with 10 % (w/v) skimmed milk powder for 1 h at room temperature. The 
membranes were then incubated in TBST-1% (w/v) milk (TBS 
supplemented with 0.1 % (v/v) Tween 20 (TBST) and 1 % (w/v) skimmed 
milk powder) with anti-caveolin1 (1:200) overnight at 4 °C. After three 5 
min washes with TBST, the membranes were incubated in TBST-5 % milk 
(TBST supplemented with 5 % (w/v) skimmed milk powder) with anti-
rabbit-HRP secondary antibody (A0545, Sigma Aldrich Ltd) (1:5,000) for 1 
h at room temperature. After at least three 5 min washes with TBST, the 
membranes were developed using the SuperSignal West Pico 
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chemiluminescent substrate (Pierce, Thermo Fisher Scientific, 
Northumberland, UK). 
3.5.4.3 Heparin affinity chromatography   
Membrane pellets P2-P5 were selected according to their sedimentation 
profile and caveolin-1 signal intensity. The resuspended pellets were 
pooled, adjusted to 0.15 M NaCl and 1 % (v/v) Triton X-100 and were 
applied to a 1 ml Hi-Trap heparin column (GE Healthcare Life Sciences) 
equilibrated with a modified phosphate-buffered saline (PBS), buffer WL 
(0.15 M NaCl, 13.7 mM Na2HPO4, 6.3 mM NaH2PO4, 0.1 % (v/v) Triton X- 
100, pH 7.2). After loading, the column was extensively washed with buffer 
WL until the absorbance at 280 nm reached the baseline. Bound proteins 
were then eluted with a 1-column volume of buffer E (2 M NaCl, 13.7 mM 
Na2HPO4, 6.3 mM Na2HPO4, 0.1 % (v/v) Triton X-100, pH 7.2). Protein 
concentration was measured by the BCA protein assay. 
3.5.4.4 Sample preparation for mass spectrometry  
Seventy percent (w/v) trichloroacetic acid (TCA) was added to an equal 
volume of the heparin-bound fraction to obtain a final concentration of 
35% (w/v) TCA. This was placed at -20°C for 1 hour, followed by 
centrifugation at 14,000 rpm for 10 minutes. After removing the 
supernatant carefully with a glass pipette, the pellet was washed 5 times 
with 5% (w/v) TCA. The pellet was freeze-dried overnight, washed 
subsequently with 0.5 mL of diethyl ether to remove the excess TCA and 
centrifuged at 5000 rpm. The supernatant was removed and the diethyl 
ether wash was repeated 2 more times. The final pellet was left to dry in 
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the fume hood. The ether-washed, TCA-precipitated pellets were 
resolublised in either 200 µL (normal pancreas (NP)) or 600 µL (acute 
pancreas (AP)) of 50 mM ammonium bicarbonate, 0.05% (v/v) Rapigest 
(Waters, Manchester, UK) and shaken at 550 rpm for 10 min at 80°C. The 
sample was then reduced (addition of 10 µL (NP) or 30 µL (AP) of 60 mM 
DTT and incubation at 60 °C for 10 minutes) and alkylated (addition of 10 
µL (NP) or 30 µL (AP) of 180 mM iodoacetamide and incubation at room 
temperature for 30 minutes in the dark). Trypsin (Sigma, Poole, UK, 
proteomics grade) was reconstituted in 50 mM acetic acid to a 
concentration of 0.2 µg/µl and 10 µL (NP) or 30 µl (AP) added to the 
sample followed by overnight incubation at 37°C. The digestion was 
terminated and RapiGest™ removed by acidification (3 µL (NP) or 9 µL (AP) 
of TFA and incubation at 37°C for 45 min) and centrifugation (15,000 x g 
for 15 min). To check for complete digestion each sample was analysed 
pre- and post-acidification by SDS-PAGE. 
3.5.4.5 Mass spectrometry data acquisition and analysis   
For LC-MS/MS analysis each digest was diluted to 250 ng/µL with 97/3/0.1 
% (v/v) water/acetonitrile/formic acid and mixed 2:1 with a protein digest 
standard (50 fmol/µL yeast alcohol dehydrogenase, Mass PREP™ Digestion 
Standard, Waters). A 3 µL injection of this mixture, corresponding to 500 
ng of sample and 50 fmol of standard was analysed using an Ultimate 3000 
RSLC™ nano system (Thermo Scientific, Hemel Hempstead, UK) coupled to 
a QExactive™ mass spectrometer (Thermo Scientific). The sample was 
loaded onto the trapping column (Thermo Scientific, PepMap100, C18, 300 
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μm X 5 mm), using partial loop injection, for 7 minutes at a flow rate of 4 
μL/min with 0.1% (v/v) TFA. The sample was resolved on the analytical 
column (Easy-Spray C18 75 µm x 500 mm 2 µm column) using a gradient of 
97% A (0.1% formic acid) 3% B (99.9% acetonitrile, 0.1% formic acid) to 
60% A 40% B (all v/v) over 90 minutes at a flow rate of 300 nL/min. The 
data-dependent program used for data acquisition consisted of a 70,000 
resolution full-scan MS scan (automatic gain control (AGC) set to 1e6 ions 
with a maximum fill time of 250 ms) the 10 most abundant peaks were 
selected for MS/MS using a 17,000 resolution scan (AGC set to 5e4 ions 
with a maximum fill time of 250 ms) with an ion selection window of 3 m/z 
and a normalised collision energy of 30. To avoid repeated selection of 
peptides for MS/MS, the program used a 30 second dynamic exclusion 
window. 
The data were processed with Progenesis QI (version 2 Nonlinear 
Dynamics, Newcastle upon Tyne, UK). Samples were aligned according to 
retention time using a combination of manual and automatic alignment. 
Default peak picking parameters were applied and features with charges 
from 1+ to 4+ featuring three or more isotope peaks were retained. 
Database searching was performed using Mascot (Matrix Science, London, 
UK). A Mascot Generic File, created by Progenesis QI, was searched against 
the reviewed entries of the reference proteome set of M. musculus from 
Uniprot (19/02/2014, 43238 sequences) with the sequence of yeast 
alcohol dehydrogenase (UniProt: P00330) added. A fixed carbamidomethyl 
modification for cysteine and variable oxidation modification for 
methionine were specified. A precursor mass tolerance of 10 ppm and a 
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fragment ion mass tolerance of 0.01 Da were applied. The results were then 
filtered to obtain a peptide false discovery rate of 1% and a requirement of 
two peptides per protein was applied. Label-free quantification was 
performed following the “Top3” methodology (Silva et al., 2006) by spiking 
the sample prior to analysis with an internal standard of 50 fmol yeast 
alcohol dehydrogenase digest (Uniprot P00330, Waters). Proteins were 
annotated as differentially expressed if they achieved a false discovery rate 
(FDR) corrected q value of 1%. Additionally, an adjusted threshold p value 
of less than 0.001 following the Bonferroni correction was used to identify 
the HBPs as potential biomarkers in the first instance (Ting et al., 2009). 
3.5.4.6 Identification of the extracellular HBPs in NP and AP 
 Extracellular proteins were identified using a combination of 
bioinformatics tools. SignalP 4.1, which predicts the presence of a secretory 
signal peptide, was used to identify extracellular proteins (Petersen et al., 
2011) with Phobius, which is a combined transmembrane topology and 
signal peptide prediction tool, to obtain a wider coverage for extracellular 
protein identification (Kall et al., 2007). A third tool was SecretomeP 2.0, 
which produces ab initio predictions of protein secretions not based on    a 
secretory signal peptide (Bendtsen et al., 2004). A fourth tool based on 
ontology, Ingenuity Pathways Analysis (IPA), was used to identify 
extracellular and plasma membrane proteins. The HBPs that were not 
identified using SignalP, Phobius, or SecretomeP but which were identified 
using IPA were further investigated using a manual approach. Each 
candidate HBP was examined using UniProtKB for the presence of an 
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extracellular signature. A search in Pubmed, using the terms “extracellular” 
or “secreted” was performed to investigate those proteins that still had an 
ambiguous subcellular location to identify at least one publication 
demonstrating an unequivocal plasma membrane and or extracellular 
localisation.   Finally, the outputs of the various approaches were merged to 
obtain the final list of HBPs in NP and AP.  
 
3.5.4.7 Interactions and construction of networks of HBPs  
Interactions between HBPs were obtained from the online database 
resource ‘Search Tool for the Retrieval of Interacting Genes’ (STRING). 
STRING 9.1 is a database of known and predicted functional interactions 
and served as a ‘one-stop’ comprehensive resource that could be easily 
used with Cytoscape (Franceschini et al., 2013). The interactions in STRING 
are provided with a probabilistic confidence score that is an estimate of 
how likely an interaction describes a functional linkage between two 
proteins. A higher score indicating a higher confidence is given when more 
than one type of information supports a given association. Only 
interactions with a high confidence score (0.70 and above) were used to 
build networks using Cytoscape 2.8.1, which is an open source, Java based 
bioinformatics package for biological network visualization (Smoot et al., 
2011). The resulting networks were termed ‘protein interactomes’. In the 
protein interactomes, HBPs or ‘nodes’ are coloured blue, while the black 
lines connecting the HBPs denote the interactions or ‘edges’. 
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3.5.4.8 Network Analysis 
3.5.4.8.1 Network parameters 
Additional ‘plugins’ or tools in Cytoscape were used for analysis. The 
networks were treated as undirected and the following parameters were 
computed using the ‘NetworkAnalyzer’ plugin (Assenov et al., 2008): 
diameter, average number of neighbours, number of connected pairs of 
nodes, node degree, average clustering coefficient, topological coefficient, 
and shortest path length. We used the ‘clustering coefficient’ and ‘number 
of connected components’ as measures of network connectivity. A high 
clustering coefficient and a low number of connected components are 
present in well-connected networks (Barzel and Biham, 2009).  
3.5.4.8.2 Identification of potential biomarkers and therapeutic targets  
Canonical pathways and cluster analysis were used in conjunction with 
differential expression as tools to identify potential functional biomarkers 
and drug targets. 
 
Canonical pathways and bio-functions analyses  
Canonical pathways are well-characterized signalling pathways that have 
been curated from original data. Bio-functions are molecular and cellular 
functions that play important roles in homeostasis in health and disease. 
The significance of the association between the datasets and the canonical 
pathway/bio-function was measured by calculating the p-value using 
Fisher’s exact test to determine the probability of the association between 
the HBPs in the dataset and the canonical pathway/bio-function. Canonical 
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pathways and bio-function analyses are useful tools for the identification of 
potential biomarkers and drug targets. They also help identify biological 
pathways that play important roles in homeostasis and complex diseases. 
 
Cluster Analysis  
Clusters, which are highly interconnected hubs of nodes (HBPs) within the 
networks, were identified using the ‘AllegroMCODE’ plugin in Cytoscape. 
Clusters are scored depending on the number of constituent nodes and the 
edges (interactions) between them. 
3.5.4.8.3 Comparing the connectivity of the heparin-binding protein 
interactome with other extracellular protein interactomes  
An updated list of HBPs was obtained combining the list of HBPs from Ori 
et al. 2011 (Ori et al., 2011) and the HBPs from the experiments described 
here. The complete human proteome was obtained from the protein 
knowledgebase in UniProtKB, using the following search “Homo sapiens 
(Human) [9606]" AND keyword: "Complete proteome [KW-0181]". The 
extracellular proteome was extracted using the following Gene Ontology 
(GO) terms: GO:0005576 (extracellular region), GO:0005615 (extracellular 
space), GO:003102 (extracellular matrix- ECM) and GO:0005604 (basement 
membrane).   Clustering coefficients of extracellular protein interactomes 
were compared in order to ascertain if the heparin-binding protein 
interactomes formed important modules within the extracellular space. 
The extracellular non-HBP protein list was generated by subtraction of the 
HBP list from the whole extracellular protein list. The extracellular protein 
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interactome (Ec), the extracellular non heparin-binding protein 
interactome (Ec_not hepint) and the extracellular heparin-binding protein 
interactome (Ec_hepint) were built in Cytoscape using the respective lists 
obtained, as described above, and the interaction data retrieved from the 
STRING database. The heparin-binding protein interactomes (Ec_hepint) 
were also compared with their corresponding degree-preserving 
randomised versions in order to determine whether the network 
parameters arising from the interactions of the HBPs were random. The 
randomised networks (Ec_hepint_random) were generated, by shuffling the 
edges of the respective heparin-binding putative protein interactomes, 
using the ‘Random Networks’ plugin in Cytoscape Cytoscape.  A network is 
deemed to be well connected if its average clustering coefficient is 
significantly higher than that of its corresponding random networks.  
 
3.5.5 Results  
Identification of HBPs from plasma membrane enriched fractions from 
normal and a murine model of acute pancreatitis - Each HBP isolation 
experiment was performed three times using sixteen pancreases from 
control (NP) and AP mice. Acute pancreatitis was induced in animals by 
injection of caerulein. Histological analysis of samples of these pancreases 
demonstrated the classic features of normal pancreas with preserved 
acinar pattern (Fig 3.5.1A) and those associated with AP namely marked 
oedema, vacuolisation, neutrophil infiltration in the ductal margins and 
parenchyma of the pancreas, with focal acinar cell necrosis (Figs 3.5.1B).  
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Serum amylase was observed to increase ~8- to 10-fold in AP compared to 
NP (Figs 3.5.1A, B).  These data are consistent with successful induction of 
AP (Carvalho et al., 2014). 
Differential centrifugation (De Duve, 1971, Ray, 1970) of pancreas 
homogenates produced a series of cellular sub-fractions, including the final 
microsomal pellet (lane Mc, Figs 3.5.2A.A, 35.2B.A), which was floated on a 
sucrose gradient (0.77-1.55 M) to separate its individual constituents (Figs 
3.5.2A.B, 3.5.2B.B). The gradient was harvested into 12 fractions, with the 
final fraction being discarded. Eleven fractions were assessed by Western 
blot for the plasma membrane marker (caveolin-1) (Figs 3.5.2A.B, 
3.5.2B.B). The caveolin-1 content was inversely correlated with the 
equilibrium density of the sucrose fractions, consistent with plasma 
membranes, which possess lower density than other microsomal 
membranes. Fractions 2 to 4, which had the strongest caveolin-1 
immunoreactivity, were pooled and selected as the plasma membrane 
enriched fraction (PM). This was solubilised in Triton-X-100 and subjected 
to heparin affinity chromatography. After extensive washing the heparin 
column with PBS, proteins that remained bound were deemed to have a 
sufficiently strong interaction with the polysaccharide to be considered as 
HBPs.  These were eluted with 2 M NaCl and precipitated with TCA to 
remove Triton-X-100, followed by digestion with with trypsin. After 
ascertaining the optimal loading concentration, the sample order was 
randomised across biological (three each NP and AP) and technical repeats 
prior to LC-MS. The LC-MS runs were then individually searched using 
MASCOT protein search engine (www.matrixscience.com) (Perkins et al., 
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1999).  There was little variation between the technical replicates for the 
samples, which can be attributed to the high quality of the sample 
preparation and MS analysis (Fig 3.5.3). Each technical replicate produced 
between 1500-1900 protein hits at a peptide false discovery rate (FDR) of 
1%. To obtain a fuller coverage, the data were run through Progenesis 
label-free software. The merged file yielded over 1900 hits at a peptide 
false discovery rate of 1%. Using a 2-peptide stringency, these were 
reduced to 1602 proteins in NP and 1866 proteins in AP (Supplementary 
Tables 1 and 2).  
The 1602 proteins in NP and 1866 proteins in AP were then filtered by the 
bioinformatics pipeline described in "Experimental Procedures" to identify 
those possessing extracellular (partially or wholly) amino acid sequence. A 
total of 396 proteins in NP (Supplementary Table 3) and 419 proteins in AP 
(Supplementary Table 4) were identified as heparin binding and 
extracellular. Combining these two sets of proteins yielded 559 HBPs, of 
which 460 HBPs had not been identified previously as heparin binding. 
With such a substantial number of new HBPs, it was important to analyse 
their functions and relationships to gain insight into the significance of the 
pancreas and AP associated HBPs.  This was achieved by an analysis of 
their protein-protein interactions. 
 
Label-free quantification 
Using the “Top3” methodology, proteins were annotated as differentially 
expressed if they achieved a FDR corrected q value of 1% (Supplementary 
Tables 5 and 6). Introduction of a p value cut off of 0.001, following the 
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Bonferroni correction, resulted in the identification of 103 HBPs that were 
overexpressed and 116 HBPs that were under expressed in AP as 
compared to NP. Known biomarkers of AP, such as carboxypeptidase (CPB1 
and CPB2) and pancreatic amylase (AMY2A) (Gomatos et al., 2014) were 
found to be overexpressed in the AP group. TAP-binding protein (TABP or 
Tapasin) that binds to TAP (trypsinogen activation peptide) was also found 
to be overexpressed. The top 20 HBPs with the highest fold change in each 
group (Tables 3.5.1 & 3.5.2) may provide potential biomarkers for AP.  
 
Network construction and analysis of HBPs in the pancreas - The lists of 
HBPs in NP and AP were used to obtain protein-protein interactions from 
STRING.  Only interactions with a high confidence score (0.70 and above) 
were used. These were imported into Cytoscape to build heparin-binding 
protein interactomes in NP and AP. The nodes, corresponding to each HBP, 
are coloured grey and are connected to each other by black lines, which are 
also termed edges and represent the known interactions of the HBPs in NP 
(Fig 3.5.4). ‘Nodes’ or HBPs are coloured depending on their fold change 
value, based on label-free quantification, in the AP interactome (Fig 3.5.5). 
The HBPs that are under expressed in AP relative to NP appear green and 
those that are over expressed appear red. Grey lines connecting the HBPs 
denote ‘edges’ or interactions. The topological parameters of the HBP 
interactomes were obtained using ‘NetworkAnalyser’, which is a plugin in 
Cytoscape. The HBP interactomes of NP and AP have high clustering 
coefficients (NP = 0.375 and AP = 0.390). The clustering coefficients of the 
HBP interactomes were also significantly higher than those of their 
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corresponding random networks (Ec_hepint_random) in NP (p=0.001) and 
AP (p<0.001). These suggest that the HBP interactomes form highly 
interconnected modules in the extracellular space of the pancreas (Barzel 
and Biham, 2009, Dong and Horvath, 2007). This would mean that the HBP 
interactomes are likely to be central to the homeostasis of the normal 
pancreas and the HBPs identified in AP may have key roles in mediating the 
altered cell communication that is associated with AP.  To identify which 
HBPs are most likely to be disease biomarkers or targets for the 
development of therapy, specific tools in Cytoscape were used, such as 
canonical pathways, bio-functions and cluster analysis. These allow the 
HBPs in NP and AP to be associated with biological pathways and functions 
that play important roles in health and disease.  
 
Analysis of Canonical Pathways, Bio-functions of HBPs in NP and AP - The 
context of a particular HBP, that is the other HBPs, will be important, 
particularly since these proteins are clearly highly interconnected.  
Therefore, a first analysis was performed of the HBPs in NP and of AP.  A 
subsequent analysis was done on the HBPs unique to either NP or AP. 
HBPs in NP and AP clearly have functions important in cell communication 
(Fig 3.5.6) and they enrich to a number of canonical pathways (Tables 3.5.3 
and 3.5.4, Supplementary Tables 7 and 8) underlying homeostasis and 
complex diseases both at a systemic and an organ / disease level (NP and 
AP).  For example, the top canonical pathway associated with the NP 
dataset, signalling by ‘Rho family GTPases’ plays an important role in cell 
adhesion, as do a number of the other highly ranked pathways, 'RhoGDI 
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Signaling', 'Ephrin B Signaling', 'Tec Kinase Signaling', 'Actin Cytoskeleton 
Signaling' and 'Ephrin Receptor Signaling'. Cell adhesion is essential to the 
maintenance of tissue architecture and so a type of cell communication 
appropriate for homeostasis (Maitre and Heisenberg, 2013). In contrast, 
the top pathways associated with the HBPs in AP are associated with 
inflammatory responses.  Thus, the top four pathways in AP are ‘Intrinsic 
Prothrombin Activation Pathway’, ‘Coagulation System’, ‘Acute Phase 
Response Signalling’ and ‘LXR/RXR Activation’. Most of the HBPs enriching 
to these pathways were found to be overexpressed in AP relative to NP 
(Supplementary Table 5).    The presence of pathways linked to cell 
adhesion further down the list ('Actin Cytoskeleton Signaling', 'RhoGDI 
Signaling',  'Signaling by Rho Family GTPases', 'Ephrin Receptor Signaling', 
'Ephrin B Signaling' and 'Integrin Signaling'), would then reflect the 
predominance of cell motility and a change in tissue architecture, driven by 
the inflammatory pathways. 
 
Analysis of the bio-functions associated with the HBPs in NP and AP 
support the conclusions reached from the analysis of canonical pathways.  
Thus, the highest ranked bio-functions of HBPs in NP is transport of 
molecules and more specific related bio-functions are also highly ranked, 
e.g., amino acid metabolism, transport of ions, and these relate to the 
numerous anabolic functions of the pancreas (Supplementary Table 7).  
The various bio-functions relating to "Cellular Movement", "Cell 
Morphology" and "Cellular Assembly and Organization' will similarly 
reflect the architecture of homeostasis of the pancreas (Supplementary 
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Table 9).  In AP, there is a marked change in bio-functions associated with 
the HBPs, with a loss of all those associated with anabolism from the most 
highly ranked positions.  Instead, bio-functions linked to inflammation, cell 
death and disruption of tissue architecture feature (Supplementary Table 
10). 
 
The analysis of the HBPs that were unique to NP or to AP (Supplementary 
Tables 11 & 12) shows that these subsets of HBPs are also associated with 
canonical pathways and biofunctions characteristic of homeostasis and 
inflammation.  Thus, top canonical pathways enriching to the HBPs unique 
to the NP dataset (Supplementary table 13) also relate to anabolism, but 
specifically to mitochondrial function, whereas the unique HBPs of AP are 
again associated with inflammation (Supplementary Table 14 and Fig. 
3.5.7). In terms of bio-functions, the HBPs unique to the NP dataset 
similarly enrich to anabolic bio-functions (Supplementary Table 15) and 
those of AP to ones associated with inflammation (Supplementary Table 
16). 
 
Cluster analysis 
The top clusters in AP include HBPs that are mainly over expressed 
compared to NP using label-free quantification (Supplementary Table 17). 
These clusters enrich to a number of canonical pathways that are linked to 
the AP dataset.  
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The global heparin interactome - A total of 559 extracellular HBPs were 
identified in the present work, of which 460 proteins have not been 
previously identified previously as being heparin binding (Ori et al., 2011). 
This takes the number of extracellular HBPs from 435 previously known to 
883 (Supplementary Table 18), which is a significant increase. It was, 
therefore, important to determine whether the enlarged HBP interactome 
retained functional relevance in the extracellular space. This was 
accomplished by a comparison of clustering coefficients of various 
extracellular protein-protein interaction networks. The clustering 
coefficient of the extracellular HBP interactome (Ec_hepint) was 
significantly higher than that of the whole extracellular interactome (Ec) 
and the extracellular non-HBP interactome, as well that of the 
corresponding randomised version of Ec-hepint (Ec-hepint_random) (Fig. 
3.5.8). This indicates that even with 460 additional members the HBPs 
remain highly interconnected and form an important regulatory module in 
the extracellular space. The global heparin interactome enriches to 
important canonical pathways (Supplementary Table 19); some have a 
clear pancreas bias, due to the fact that the new HBPs have been discovered 
in this organ. For example, ‘Hepatic Fibrosis / Hepatic Stellate Cell 
Activation’ (-log (p-value) = 3.78E01), which is the top pathway associated 
with the global HBP interactome is of particular relevance in pancreatic 
homeostasis, since the pancreatic stellate cell is known to play an 
important role in this tissue (Vonlaufen et al., 2007). 
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3.5.6 Discussion 
Extracellular HBPs have been shown previously to be functionally 
associated to physiological and pathological processes.  The aim of the 
present work was to determine if this was true for a single organ, the 
pancreas and one of its diseases, AP.  The focus was on extracellular HBPs, 
because these could readily be distinguished from intracellular 
contaminants.  However, it is important to note that there is clear evidence 
for intracellular HS (Courvalin et al., 1982, Bornens, 1973) However, there 
is no means at present to distinguish in the output from a proteomic 
experiment intracellular proteins that interact with intracellular HS from 
those that interact solely with another intracellular polyanion, such as 
phosphorylated lipids and nucleic acids.   For this reason intracellular 
proteins are excluded from the analysis, though there are substantial 
numbers present in the analysis. 
Differential centrifugation followed by density gradient centrifugation was 
used to isolate a plasma membrane enriched subcellular fraction, which 
was subsequently used as a source of extracellular HBPs (Ray, 1970).  In 
addition to membrane proteins, which are often underrepresented in 
proteomic analyses, this fraction would also encompass intra- and 
extracellular associated membrane proteins, as well as proteins associated 
with the pericellular matrix.  The plasma membrane enriched fraction was 
solubilized using a non-ionic detergent and subjected to heparin-affinity 
chromatography. In contrast to previous work (Ori et al., 2011), here a 
single elution at 2M NaCl was used to recover heparin-binding proteins. 
The rationale was that the concentration of NaCl required for elution from 
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heparin does not necessarily correlate with affinity for HS (Xu et al., 2012).  
A number of tools were used to identify proteins with significant sequences 
in the extracellular space, including SignalP, Phobius, SecretomeP, IPA and 
manual curation for the presence of an extracellular signature using 
Uniprot-KB and PubMed. In a previous analysis of rat liver a bioinformatics 
pipeline based on ontology (gene ontology and ingenuity ontology, IPA) 
was combined with manual curation to identify 62 HBPs, of which 12 were 
previously known to bind to heparin (Ori et al., 2011). Middaugh et al., 
employing an antibody array on total cell lysate before and after depletion 
of HBPs by heparin agarose beads, identified 29 proteins whose signal was 
significantly reduced after incubation of the cell lysate with heparin beads, 
though only three were extracellular (Jones et al., 2004). Our present 
approach identified 460 new extracellular HBPs and has more than 
doubled the number of proteins that may be HBPs (Ori et al., 2011). This 
increase is likely due to the new source of tissue and an associated disease 
state, the purification of a plasma membrane enriched sub-proteome, the 
depth of the mass spectrometry analysis and the use of parallel approaches 
to identify proteins that possess significant extracellular sequence.  
An important question is how representative are the HBPs identified here 
of the proteins in NP and AP whose function depends on, or is modified by, 
interaction with HS.  The mass spectrometry is limited by the depth of the 
analysis is limited by only accepting identifications based on at least two 
peptides and a maximum false discovery rate of 1%. This in itself leads to 
false positives and false negatives. The Bonferroni correction was used to 
increase the stringency and further reduce the number of false positives for 
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the purpose of biomarker identification, (Ting et al., 2009). 
There are additional factors that are likely to contribute to the false 
positives and false negatives. Some higher abundance HBPs may escape 
detection, because they are part of large macromoleuclar assemblies that 
are not solubilised by Triton-X-100, associated with, for example, matrix 
fibrils, membrane microdomains or cytoskeleton.  Moreover, not all HS-
binding proteins will necessarily bind the heparin column and may, instead 
remain bound to HSPGs during affinity chromatography.  Indeed, the 
transition and S-domains of HS have far more diverse structures than 
heparin (Ori et al., 2008, Xu and Esko, 2014).  Thus, the present analysis 
will have a bias towards HBPs that bind structures present in the 
trisulfated disaccharide repeat of heparin, which makes up 75% of the 
polysaccharide and contains 2-O sulfated iduronate, N-, 6-O sulfated 
glucosamine.  A source of false positives would be proteins that are bound 
to an HBP with a sufficiently slow dissociation rate constant that they 
would be carried though the affinity chromatography, an interaction, which 
would be consistent with biological function.  
A recurrent question is how specific or selective is a protein-HS interaction 
(Xu and Esko, 2014, Ori et al., 2008, Xu et al., 2012).  This will be important 
in terms of understanding the mechanism whereby HS regulates the 
activity of a protein.  HS has been shown directly to control the movement 
of a protein, fibroblast growth factor-2 in the pericellular matrix (Duchesne 
et al., 2012).  Thus, even an unselective charge-dependent interaction of a 
protein with HS will restrict the movement of the protein in the 
extracellular space and so affect its function in terms of location and local 
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concentration.  Therefore, proteins that bind heparin in PBS and that 
remain so during the extensive washing of the affinity column have a 
relatively slow dissociation rate constant and would be expected to have at 
least their movement and extracellular location regulated by HS. Taking 
into account the caveats described above regarding false positives, the 
HBPs identified here are thus likely have at least this aspect of their 
function regulated in this way by HS in the extracellular space of NP and 
AP. Any changes in the structure of HS that might accompany AP may, 
therefore, alter the movement/location of the HBP and so its contribution 
to cell physiology.  
Apart from the limits imposed on the mass spectrometry analysis, the other 
sources of false positives and negatives are not currently quantifiable, until 
such time as the interaction of each HBP with the polysaccharide is 
measured directly. 
Given the above caveats, the heparin interactome is now substantially 
larger that previously described (Ori et al., 2011).  Importantly, the protein-
protein interaction network of the HBPs retains the key properties of the 
earlier, smaller interactome and hence its functional relevance to the 
regulation of cell communication by extracellular proteins (Ori et al., 2011). 
Thus, the HBP interactome is highly interconnected and HBPs form 
numerous regulatory modules in the extracellular space. Importantly, this 
is true for the subset of HBPs expressed by a single organ, the pancreas, one 
of its associated diseases, AP, and for the global interactome. Thus, it may 
be that for most, if not all organs, HBPs represent the most interconnected 
set of extracellular proteins, and, therefore, those with the greatest 
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regulatory potential. 
Intriguingly, the present work identified some non-canonical extracellular 
HBPs such as NDUFS4, NDUFS6, NDUFS7, NDUFS8, NDUFA9, NDUFA10 in 
NP, and NDUFA9 and NDUFA10 in NP and AP. These are mitochondrial 
proteins that are nuclear-encoded and were identified by SignalP, Phobius 
or SecretomeP as having a secretory signal.  It seems unlikely that they are 
simply contaminants with polyanion binding properties that allow 
interaction with heparin. Direct evidence of extracellular localisation has 
been obtained for multiple subunits of the ATP synthase complex, including 
the OSCP (Oligomycin sensitivity-conferring protein) and D subunits, which 
have been observed at the plasma membrane (Moser et al., 1999, 
Vantourout et al., 2008, Yonally and Capaldi, 2006). Such proteins with a 
clearly established classic subcellular localisation, which are subsequently 
found, associated with other organelles or extracellularly, have been 
termed to be 'moonlighting'. We, therefore, included the NDUF proteins as 
extracellular HBPs. Though their plasma membrane/extracellular 
localisation remains to be confirmed by orthogonal measurements, the 
observation that these are all present in NP, but are under-expressed in AP 
is consistent with the contribution of mitochondrial dysfunction to AP 
(Cardenas et al., 2010, Pinton et al., 2008, Koopman et al., 2010). 
A number of biomarkers that have been previously investigated in AP, such 
as carboxypeptidase B and pancreatic amylase,were identified in the AP 
dataset (Table 1 and Supplementary Table 5). LBP, an acute phase reactant, 
with a rise and fall in serum that is similar to CRP (Rau et al., 2003) and 
which is protective in AP, was identified to be over expressed in the AP 
 124 
dataset. HRG (Table 1) has been shown to recruit IgG to facilitate clearance 
of necrotic cells by pahagocytes (Poon et al., 2010). Thus, the HBPs 
exhibiting the greatest fold change (Table 1) alone or in combination with 
existing biomarkers may provide an early stratification of AP, identifying 
the severe form of the disease earlier and improving outcomes. The top 
canonical pathways and clusters, to which the HBPs in the AP dataset 
enrich, provide a repository for functional biomarker and drug discovery in 
AP. Neutrophils have been shown to play an important role in AP, 
activating the complement system and promoting lung injury (Awla et al., 
2012, Shrivastava and Bhatia, 2010). They release platelet activating factor, 
which has been implicated as a key mediator in the progression of AP and 
is associated with increased complication rates and mortality (Xia et al., 
2007). HBPs such as PIP5K1C that participate in these canonical pathways 
regulate neutrophil adhesion by facilitating RhoA GTPase and integrin 
activation through chemoattractants (Xu et al., 2010a). Small molecule 
inhibitors of PIP5K1C have been investigated in the treatment of other 
diseases (Wright et al., 2014) and it may, useful to explore these in the 
treatment of AP. SERPINC1, has anti-inflammatory properties and has been 
shown to improve acute pancreatitis in the rat model (Hagiwara et al., 
2009). Thus, its presence among the HBPs whose expression is increased to 
the greatest extent may reflect a normal physiological reaction to the insult 
of AP.  
“Hepatic Fibrosis / Hepatic Stellate Cell Activation”, which is the top 
canonical pathway associated with the global HBP interactome and one of 
the top pathways enriching to the AP dataset is particularly relevant in 
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pancreatic homeostasis.  Stellate cells play an important role in 
inflammatory diseases and cancer of the liver, as in the pancreas 
(Vonlaufen et al., 2007, Algul et al., 2007, Masamune et al., 2009). The 
enrichment of a well-defined fibrosis and activation pathway associated 
with the hepatic stellate cell, rather than its pancreatic counterpart is 
probably due to the fact that the former was discovered earlier and has 
been studied more extensively (Geerts, 2001). Hepatic and pancreatic 
stellate cells exhibit similarities of morphology and function and are 
activated by common cytokines and growth factors, and may share a 
common origin (Buchholz et al., 2005). FN1 and CD14, which are unique to 
the AP dataset (so highly increased relative to NP) and also enriched to the 
‘Hepatic Fibrosis / Hepatic Stellate Cell Activation’ pathway may thus have 
potential as a PSC specific biomarker and drug target in the progression of 
AP to chronic pancreatitis. Indeed, Rhein, which is a natural anthraquinone 
targeting the SHH/GLI1 signalling pathway in pancreatic fibrosis, is 
presently being investigated as an anti- fibrotic drug in the pancreas (Tsang 
et al., 2013). HBPs such as vascular endothelial growth factor A (VEGFA) 
and fibroblast growth factor2 (FGF2) enrich to this pathway. Thus, 
although they are not amongst the most highly expressed in AP because 
they enrich to this pathway and because there are already drugs targeting 
their receptors undergoing clinical trials, particularly for the treatment of 
various cancers, they may have application in the treatment of AP.  
‘CXCR4 Signalling’ regulates cell differentiation, cell chemotaxis cell 
survival and apoptosis, and has important roles in the embryonic 
development of the pancreas (Katsumoto and Kume, 2013). Its importance 
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as a key canonical pathway in AP is supported by the identification of its 
protective role in AP, which may be mediated by facilitating the migration 
of bone marrow derived stem cells towards the pancreas (Gong et al., 
2014). Early ‘Complement system’ activation occurs in pancreatic necrosis 
and suggests this pathway may enable the development of treatment of 
leukocyte-associated injury in AP (Hartwig et al., 2006).  In this respect, 
heparin-based compounds (Coombe and Kett, 2005) might be particularly 
interesting as potential therapeutics for AP.  They may be tuneable to 
modulate a gamut of HBPs important in the cell communication underlying 
the progression of AP, which could include complement system activation, 
growth factors and cytokines, and, because heparin can modulate the 
activity of some transporters, metabolism (Chen et al., 2014). 
The HBPs define a group of proteins that have a clear functional 
importance in cell communication in homeostasis and in at least one 
disease, AP.  HBPs are experimentally accessible, because they bind to 
heparin and are extracellular, and in at least some instances they will be 
present in serum.  Therefore, the HBPs of pancreas and AP are likely to 
yield much-needed biomarkers and targets for therapy, a conclusion 
reinforced by the observation that some of the HBPs identified are involved 
known mechanisms of AP and some are current targets for therapy in AP 
and other diseases.  
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 HBP            Max fold change 
ERP27 412 
CPB2 90 
Ngp 79 
HRG 77 
Try4 58 
SERPINC1 44 
ITIH2 43 
PLG 43 
COL6A3 41 
SERPIND1 37 
CTRC 36 
FN1 35 
AHSG 30 
Pzp 30 
SERPINA1 28 
COL1A2 26 
PRG2 23 
SERPINA3 21 
F2 20 
Ear3 
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Table 3.5.1. Top 20 HBPs upregulated in AP. The upregulated HBPs were filtered 
depending on the maximum fold change values. An adjusted threshold p value of less 
than 0.001 following the Bonferroni correction was used to identify the top HBPs to be 
validated as potential biomarkers. 
 
 
HBP       Max fold change 
KLB -46 
SOSTDC1 -20 
CRIP2 -18 
SLC4A7 -13 
COMTD1 -13  
MRGPRF -12 
RNASE1 -12 
GPR39 -11 
SLC35A2 -11 
SLC4A2 -11 
PDHA1 -10 
KCNQ1 -10. 
ARCN1 -10 
COMMD10 -10 
TMEM115 -9 
INSR -9 
TFRC -8 
CLPS -8 
ADCY6 -7 
CLTB -7 
 
Table 3.5.2. Top 20 HBPs downregulated in AP. The downregulated HBPs were 
filtered depending on the maximum fold change values. An adjusted threshold p value 
of less than 0.001 following the Bonferroni correction was used to identify the top 
HBPs to be validated as potential biomarkers. 
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Canonical Pathways 
 -log (p-
value) 
Signaling by Rho Family GTPases 8.45 
G Beta Gamma Signaling 8.44 
RhoGDI Signaling 8.16 
CXCR4 Signaling 7.28 
Caveolar-mediated Endocytosis Signaling 6.94 
IL-1 Signaling 6.77 
Thrombin Signaling 6.76 
Clathrin-mediated Endocytosis Signaling 6.32 
Ephrin B Signaling 5.91 
Tec Kinase Signaling 5.71 
Role of NFAT in Regulation of the Immune 
Response 5.23 
CREB Signaling in Neurons 5.17 
Cardiac Hypertrophy Signaling 5.12 
Role of Tissue Factor in Cancer 5.11 
Relaxin Signaling 4.76 
Actin Cytoskeleton Signaling 4.75 
Gαi Signaling 4.73 
Triacylglycerol Degradation 4.71 
Ephrin Receptor Signaling 4.55 
Sertoli Cell-Sertoli Cell Junction Signaling 4.30 
 
Table 3.5.3. Top 20 canonical pathways in normal pancreas using Ingenuity 
Pathways Analysis. The significance of the association between the datasets and the 
canonical pathway was measured by calculating the p-value using Fisher’s exact test to 
determine the probability of the association between the HBPs in the dataset and the 
canonical pathway. 
 
 
 
Canonical Pathways 
 -log (p-
value) 
Intrinsic Prothrombin Activation Pathway 14.3 
Coagulation System 13.2 
Acute Phase Response Signaling 11.4 
LXR/RXR Activation 11.0 
Clathrin-mediated Endocytosis Signaling 10.6 
FXR/RXR Activation 10.4 
Extrinsic Prothrombin Activation Pathway 9.08 
G Beta Gamma Signaling 9.02 
Complement System 7.82 
Actin Cytoskeleton Signaling 7.70 
RhoGDI Signaling 7.70 
Role of Tissue Factor in Cancer 7.30 
Signaling by Rho Family GTPases 7.23 
Ephrin Receptor Signaling 7.01 
CXCR4 Signaling 6.88 
Caveolar-mediated Endocytosis Signaling 6.64 
Ephrin B Signaling 6.58 
Virus Entry via Endocytic Pathways 6.40 
Thrombin Signaling 6.34 
Integrin Signaling 6.19 
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Table 3.5.4. Top 20 canonical pathways in experimental acute pancreatitis using 
Ingenuity Pathways Analysis. The significance of the association between the 
datasets and the canonical pathway was measured by calculating the p-value using 
Fisher’s exact test to determine the probability of the association between the HBPs in 
the dataset and the canonical pathway. 
 
 
                                         
                                         
Figure 3.5.1: Normal pancreas (NP) and caerulein-induced acute pancreatitis (AP). Representative images of H&E stained histology slides of A) NP 
and B) AP. Mean serum amylase levels in (C) NP and (D) AP in each experiment consisting of 16 individuals. 
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Figure 3.5.2: Preparation of a plasma membrane enriched fraction. Coomassie-stained SDS-PAGE gel of (A) NP and (B) AP samples obtained during 
homogenisation and fractionation by sequential steps of centrifugation. Nu = nuclear pellet; S1 = post-nuclear supernatant; Mt = mitochondrial pellet; S2 = 
post-mitochondrial supernatant; C = cytosol (post-microsomal supernatant); W = wash of the microsomal pellet; Mc = microsomal pellet. Coomassie-stained 
SDS-PAGE and western blot analysis of 10 fractions (F1-F11) from the microsomal pellet after flotation on a sucrose gradient (0.25 - 2 M) in (C) NP and (D) 
AP. Fractions are ordered depending on their equilibrium density from light (left) to heavy (right). The enrichment of plasma membrane was assessed by 
western blot using an antibody against caveolin-1, which is a specific plasma membrane marker. 
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Figure 3.5.3: Heat map depicting the variation across the biological and technical replicates. The rows represent the various biological replicates in 
normal pancreas (NP) and acute pancreatitis (AP), while the columns represent proteins. Red represents over expression and green represents under 
expression. 
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Figure 3.5.4: The heparin-binding putative protein interactome in normal pancreas (NP) constructed using Cytoscape 2.8.1. ‘Nodes’ or HBPs are 
coloured grey. Grey lines connecting the HBPs denote ‘edges’ or interactions.   
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Figure 3.5.5: The heparin-binding putative protein interactome in acute pancreatitis (AP) constructed using Cytoscape 2.8.1. ‘Nodes’ or HBPs are 
depending on their fold change value, based on label-free quantification. The HBPs that are under expressed in AP appear in green and those that are over 
expressed appear in red. Grey lines connecting the HBPs denote ‘edges’ or interactions.  
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Figure 3.5.6: Functional groups of HBPs in (A) Normal pancreas (NP) and (B) Acute pancreatitis (AP). HBPs constitute important functional groups in 
NP and AP. A number of HBPs not previously known to bind to heparin have been identified in this study. 
 
 
Figure 3.5.7: Canonical pathway analysis in AP. ‘Acute phase Reaction’ is one of the top 
canonical pathways enriched to the AP HBP dataset, using Ingenuity Pathways Analysis. 
The nodes outlined in magenta are HBPs from the AP dataset. 
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Figure 3.5.8: The relevance of the global heparin-binding protein interactome in the 
extracellular space. Comparison of the clustering coefficients of the global extracellular 
heparin binding protein interactome (Ec_hepint), corresponding random networks 
(Ec_hepint_random), the extracellular non heparin-binding protein interactome (Ec_not 
hepint) and the whole extracellular protein interactome (Ec). The Ec_hepint is a densely 
interconnected module in the extracellular space with a significantly higher clustering 
coefficient as compared to that of the Ec_hepint_random, Ec_not hepint and Ec.
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3.6 Comparison between transcriptomics and proteomics studies 
A comparison of the whole mRNA and proteomic datasets from the 2 studies 
showed that there were only 193 candidates common in NP and 17 common in 
AP respectively (Fig. 3.6A). When comparing the HBP datasets from the 
proteomics and mRNA studies in NP and AP, there were 17 common in NP and 3 
in AP respectively (Fig. 3.6B). This demonstrated that mRNA was not 
representative of protein in most cases as has been shown previously 
(Schwanhausser et al., 2011).  
 Proteomics mRNA Common 
NP 1602 1258 193 
AP 1866 103 17 
Table 3.6. Comparison between whole mRNA and proteomics datasets in NP and AP. The 
table outlines the common candidates in NP and AP from the 2 studies. 
 
 Proteomics mRNA Common 
NP 396 115 17 
AP 419 31 3 
Table 3.6B. Comparison between HBP mRNA and proteomics datasets in NP and AP. The 
table outlines the common candidates in NP and AP from the 2 studies. 
 
3.7 Discussion 
The aim of the present work was to determine if extracellular HBPs were 
functionally associated with physiological and pathological processes in the 
pancreas and in acute pancreatitis. As the focus of this work was on 
extracellular HBPs, intracellular proteins were excluded from the analysis. 
However, further to the bioinformatics pipeline that was used, a number of 
intracellular proteins that bind to HS, but which have a documented 
extracellular presence were included. These proteins may have possible 
‘moonlighting’ roles. In contrast to recent work (Ori et al., 2011), a single elution 
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at 2 M NaCl was used to recover HBPs, the rationale being that the 
concentration of NaCl required for elution does not necessarily correlate with 
affinity for HS (Xu et al., 2012). The present work has more than doubled the 
number of HBPs (Ori et al., 2011). This may be due to the new source of tissue 
used with its associated disease state, the purification of a plasma membrane 
enriched sub-proteome and the depth of mass spectrometry analysis used. Even 
though the resultant heparin-binding proteome is much larger, the protein-
protein interacting network retains the properties of the earlier, smaller 
interactome. It is highly interconnected, with HBPs forming important 
regulatory modules in the extracellular space. A number of biomarkers that 
have been previously investigated in AP, such as carboxypeptidase B and 
pancreatic amylase, were identified in AP dataset. LBP, an acute phase reactant, 
with a rise and fall in serum that is similar to CRP (Rau et al., 2003) and which is 
protective in AP, was identified to be over expressed in the AP dataset. FN1 and 
CD14, which are highly increased in AP relative to NP and also enriched to the 
‘Hepatic Fibrosis / Hepatic Stellate Cell Activation’ pathway may thus have 
potential as a pancreatic stellate cell-specific biomarker and drug target in the 
progression of AP to chronic pancreatitis. HRG has been shown to recruit IgG to 
facilitate clearance of necrotic cells by phagocytes (Poon et al., 2010). 
Neutrophils have been shown to play an important role in AP, activating the 
complement system and promoting lung injury (Awla et al., 2012, Shrivastava 
and Bhatia, 2010). HBPs such as PIP5K1C that participate in these canonical 
pathways regulate neutrophil adhesion by facilitating RhoA GTPase and integrin 
activation through chemoattractants (Xu et al., 2010a). Small molecule 
inhibitors of PIP5K1C have been investigated in the treatment of other diseases 
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(Wright et al., 2014) and may be explored in the treatment of AP. SERPINC1, has 
anti-inflammatory properties and has been shown to improve acute pancreatitis 
in the rat model (Hagiwara et al., 2009). Thus, its presence among the HBPs 
whose expression is increased to the greatest extent may reflect a normal 
physiological reaction to the insult of AP. 
The HBPs define a group of proteins that have a clear functional importance in 
cell communication in homeostasis and in AP.  By virtue of binding to heparin 
and being extracellular, the HBPs of pancreas and AP are likely to yield much-
needed biomarkers and targets for therapy.  
 
 
 
 
 
 
 
146 
Chapter 4 – Discussion and future perspectives 
 
4.1 Cell communication and HBPs 
A genome-wide analysis by Vogel and Chothia investigated the correlation 
between the expansion of superfamilies with the expansion in biological 
complexity in 38 unicellular and multicellular organisms (Vogel and Chothia, 
2006) . They used a database of 1219 hidden Markov models, based on the 
structural classification of proteins (SCOP) classification of domains, called 
Superfamily, to map the occurrence of the different superfamilies (Gough et al., 
2001). For each genome, they annotated one-domain proteins and the 
individual domains of multi-domain proteins to their respective superfamily. 
They calculated the abundance of each superfamily, as the number of proteins 
that contain at least one domain belonging to that particular superfamily. 
Normalised abundance profiles were then used to calculate a Pearson 
Correlation coefficient ‘R’, which described the correlation between superfamily 
abundance and the estimated number of cell types per genome. In order to 
establish a link between domain functions and organismal complexity, 
functional categories were assigned to each superfamily. They observed that 
194 superfamilies have a strong positive correlation (R ≥ 0.8) with organism 
complexity. However among these, 2 functional categories were responsible for 
a disproportionately high contribution, which amounted to nearly half of the 
positively correlated superfamilies. The 2 functional categories are 
superfamilies associated with extracellular processes (20 %) and regulation 
(29%) (Vogel and Chothia, 2006). Similarly, Ori et al. showed that the 
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correlation is even stronger for superfamilies that are associated with the 
heparin interactome and that HBPs form important regulatory modules in the 
extracellular space (Ori et al., 2011). Subsequently, it has been shown that HBPs 
form important regulatory modules in the pancreas and in major pancreatic 
diseases (Nunes et al., 2013). This was supported by the meta analysis of mRNA 
expression data, though such an approach rests on several assumptions (Section 
2.4).  For this reason, HBPs were analysed directly by affinity proteomics. The 
structure of this section is wrong. In general, it is better to put key findings first 
and then discuss their validity and reliability, limitations and implications. 
 
4.2 Advance in HBP identification 
Although nearly 30% of naturally occurring proteins are predicted to be 
embedded in biological membranes, membrane proteins have been traditionally 
understudied due to difficulties in solubilisation and separation (Tan et al., 
2008). The work carried out as part of this thesis has more than doubled the 
number of proteins identified as binding to heparin. This is a significant advance 
in HBP proteomics and may be due to a number of factors.  One is the new 
source of tissue and an associated disease state. Another is the streamlining of 
the HBPs purification.  Previously (Ori et al., 2011), these were split into three 
elution groups: low (0.15 M to 0.4 M NaCl), medium (0.4 M NaCl to 0.6 M NaCl) 
and high (0.6 M NaCl to 2 M NaCl).  However, it was noted that many proteins 
were found in two or more of these fractions and so this would dilute the 
sample.  This would increase the possibility of loss during subsequent sample 
processing.  In addition, the samples necessarily contained Triton-X-100 to 
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solubilise membrane proteins and the detergent had to be removed before mass 
spectrometry, as it is polydisperse and generates a lot of artefactual signal in the 
spectrum.  Originally this was achieved with a C18 Zip-tip, which is likely to 
result in considerable losses (Stewart et al., 2001).  This step was replaced by 
trichloroacetic acid (TCA) precipitation, which was validated by analysis of 
Coomassie stained gels in terms of efficacy.  While not perfect this is likely to be 
an improvement (Polson et al., 2003, Jiang et al., 2004).  Whereas the mass 
spectrometer used by Ori et al. (Ori et al., 2011) was an Orbitrap Velos, the 
instrument used for the present work was a QExactive which is housed in the 
University's Protein Function Group and is carefully maintained and calibrated. 
This would increase the depth of the analysis.  Finally, a more sophisticated 
bioinformatics pipeline was used in the present work (Section 3.1), which 
would increase the number of HBPs. 
 
However, there are caveats associated with this dataset.  One is that in some 
instances, a protein that has been identified as an HBP may in fact be bound to 
another HBP rather than directly to heparin.  If such an interaction had a 
sufficiently slow dissociation rate, the protein would be carried through the 
purification.  Such an interaction would be consistent with biological 
functionality, because of its long lifetime and would consequently produce a 
false positive. Direct heparin binding will need to be demonstrated in the newly 
discovered HBPs, but given the size of the dataset, this information will only be 
produced slowly by current biophysical methods, e.g., which require a one 
protein at a time analysis (West et al., 2005).  Sample preparation assumes that 
Triton-X-100 will efficiently solubilise all HBPs.  However, those HBPs in large 
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macromolecular assemblies, associated with matrix, membrane domains or 
cytoskeleton may not be solubilised, and so would not figure in the analysis. It is 
also assume that all HBPs will bind the heparin column.  This seems reasonable, 
but there are no data.  For example, if a HBP binds a structure found in HS, but 
not in heparin, then it could not be identified.  There is a precedent for this, 
proteins that bind to sequences containing a free amino group such a 
cyclophilin-B (Vanpouille et al., 2007).  Heparin affinity columns are usually 
made by reacting these free amines with an activated column matrix, and so 
such proteins will not be retained on the heparin affinity column.  In addition, 
the plasma membrane/matrix fraction contains both HBPs and the resident HS 
proteoglycans, so during the affinity chromatography there is likely to be 
competition between the heparin on the column and the HS of the 
proteoglycans.  Some HBPs may exchange repeatedly between the immobilised 
heparin and the HS in the mobile phase and only those that bind preferentially 
to heparin will be retained.  Thus, the affinity chromatography selects for 
proteins that engage efficiently with structures present in the classic trisulfated 
disaccharide (IdoA, 2S, GlcNS, 6S) repeat of heparin (75% of is disaccharides).  
These technical issues clearly need addressing, alongside a further question: 
does binding to heparin have any physiological significance without further 
evidence?  This is the focus of Section 4.5.   
 
4.3 HBPs and the pancreas 
The roles of HBPs in pancreas homeostasis and AP are discussed in Sections 3.2 
and 3.3.  The pancreas has important endocrine and exocrine functions and 
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plays an important role in in glucose homeostasis (Shih et al., 2013). HBPs play 
important roles in biological pathways and functions such as ion transport, 
cellular movement, adhesion, and mitochondrial function etc. underlying 
pancreatic homeostasis. Acute pancreatitis is a leading cause of hospital 
admissions and the severe form of the disease is associated with a high 
mortality (Wu and Banks, 2013, Schneider et al., 2010). In the absence of 
definitive treatment, the management remains mainly supportive. Also, no 
single laboratory marker or score can accurately predict outcome in AP 
(Mounzer et al., 2012). A number of HBPs have been identified, such as HRP, 
CD14 and FN1, that may be explored alone or in combination with existing 
biomarkers and scoring systems. These need to be validated using high quality 
samples with the associated clinical data from patients with acute pancreatitis. 
By virtue of binding to heparin, the HBP sub-proteome is easily accessible in 
tissue and body fluids, which is particularly important in biomarker and drug 
development. Interestingly, the top canonical pathway that the new global HBP 
interactome enriches to is the “Hepatic Fibrosis / Hepatic Stellate Cell 
Activation”. Hepatic and pancreatic stellate cells exhibit similarities of 
morphology and function and are activated by common cytokines and growth 
factors, and may share a common origin (Buchholz et al., 2005). Experiments 
relating to pancreatic stellate cells indicate that they play an important role in 
AP (Vonlaufen et al., 2007). HBPs such as VEGFA and FGF2 that enrich to this 
canonical pathway may be used in developing pancreatic stellate cell-specific 
therapies. Other HBPs that may be explored in drug development in AP include 
SERPINC1 (Hagiwara et al., 2009), which has potent anti-inflammatory 
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properties and PIP5K1C that has been investigated in other diseases (Wright et 
al., 2014). 
 
4.4 Moonlighting roles of HBPs 
The heparin affinity proteomics approach identified a number of non-canonical 
extracellular HBPs such as NDUFS4, NDUFS6, NDUFS7, NDUFS8, NDUFA9, 
NDUFA10 in NP, and NDUFA9 and NDUFA10 in NP and AP. These are nuclear-
encoded mitochondrial proteins. Sub-cellular fractionation using differential 
centrifugation removes mitochondria efficiently and it seems unlikely that these 
HBPs are simply contaminants with polyanion binding properties that allow 
them to interact with heparin.  In support of this argument is the fact that 
nuclear encoded mitochondrial nucleic acid binding proteins were not 
identified. Glycosylated isoforms of a number of nuclear encoded mitochondrial 
proteins have been identified at the plasma membrane (Burnham-Marusich and 
Berninsone, 2012, Moser et al., 1999, Vantourout et al., 2008, Yonally and 
Capaldi, 2006). Nuclear proteins such as histones and HMGB1 (high-mobility 
group box 1), as well as cytosolic proteins, which are found extracellularly, 
under conditions of cell stress, are termed DAMPS (damage associated pattern 
molecules) (Agalave and Svensson, 2014, Krysko et al., 2012). HBPs with a 
clearly established classic subcellular localization and which are subsequently 
found associated with other organelles or extracellularly, have been termed to 
be 'moonlighting'. ‘Moonlighting proteins’ are being increasingly identified and 
studied with a view to unraveling their roles in biological processes as well as in 
drug development. The enzyme adenosine deaminase has been shown to act as 
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a catalyst for intracellular and extracellular purine metabolism, as well as a 
costimulator for the proliferation of T-cells (Cortes et al., 2015). G protein 
coupled-receptors (GPCRs) heteroreceptor protomers act as moonlighting 
proteins and are being investigated as targets in neurotherapeutics (Fuxe et al., 
2014). Computational methods are also being used to characterize moonlighting 
proteins (Khan and Kihara, 2014, Khan et al., 2012, Gomez et al., 2003, Gomez et 
al., 2011). The NDUF proteins have therefore been included as extracellular 
HBPs, though their extracellular localisation needs documentation by 
orthogonal means.  
 
4.5 The non-extracellular HBPs 
In both NP and AP, approximately 75% of proteins identified by mass 
spectrometry were deemed not to be extracellular. In due course, evidence may 
accrue to suggest that some of these may turn out to be moonlighting proteins.  
However, this is likely to only explain the presence of some of these proteins in 
the heparin-bound fraction.  Polyanion-binding proteins from cell lysate have 
been analysed previously (Jones et al., 2004). In this work no subcellular 
fractionation was performed and only 3 proteins were extracellular.  The large 
numbers of intracellular polyanion binding proteins derive this property from 
interactions with nucleic acids and phospholipids, including phosphoinositols, 
and anionic surfaces on proteins e.g. transcriptional enhancer factor TEF-1.  In 
the present work, a plasma membrane fraction was applied to the heparin 
affinity column; intracellular proteins binding to the membrane would be 
expected to be contaminants.   
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However, classing these proteins as simple contaminants may miss important 
functional associations and is not necessarily the best explanation for the 
presence of other intracellular proteins.  For example, a considerable number of 
cytoskeletal and intracellular signalling-associated proteins were identified 
Some of these may be present due to physical association with plasma 
membrane receptor systems, which are themselves engaged with extracellular 
heparin-binding proteins.  That there are differences in these proteins between 
NP and AP may be reporting of fundamental differences in cell adhesion and cell 
signalling, though this would require a fully quantitative measurement of 
proteins to establish the biological significance of such differences.  Other 
proteins may simply relocate during tissue homogenisation, from one polyanion 
to another.  However, this would require that they are relatively weakly bound, 
able to exchange and bind more strongly to either plasma membrane 
phospholipids or extracellular HS.  
There is also an intriguing possibility that some of the of intracellular proteins 
identified in the present work may in fact be HBPs.  This is because of the 
growing evidence for the translocation of HS from the extracellular space to the 
nucleo-cytoplasmic compartment.  Early papers used heparin in procedures to 
stain nuclear proteins without having to hydrolyse DNA or to purifiy nuclear 
components (Labelle and Briere, 1971, Courvalin et al., 1982, Bornens, 1973).  
Possibly building on the idea that nuclear proteins bind heparin, pioneering 
work indicated that HS was present in the nucleus of cultured hepatocytes and 
involved in the regulation of their growth (Ishihara et al., 1986, Fedarko and 
Conrad, 1986, Fedarko et al., 1989). This remained a curiosity, until 
proteoglycan core proteins were characterised and new tools were developed. 
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There has since been a steady growth of papers relating to the presence of 
intracellular HS and HSPGs in a variety of contexts, such as translocation 
mechanisms from the extracellular space to the nucleus, sperm nuclei 
decondensation, esophageal keratinocyte differentiation and cancer 
(Richardson et al., 2001, Cheng et al., 2014, Romanato et al., 2008, Kobayashi et 
al., 2006, Purushothaman et al., 2011, Cheng et al., 2001). Allied to this work, is 
the growing body of evidence for the translocation of extracellular HBPs to the 
nucleus from the extracellular space, for example FGFs and their tyrosine kinase 
receptors, FGFRs (Coleman et al., 2014a), which may be particularly relevant to 
pancreatic stellate cell function and pancreatic cancer (Coleman et al., 2014b). 
Thus, at least some of the intracellular proteins identified here may be genuine 
HBPs, in that binding to intracellular HS affects their function and so cell 
signalling.  However, it is not possible at present to distinguish adventitious 
binding to heparin of intracellular proteins during the affinity chromatography 
step from physiologically relevant binding. 
 
4.6 Future perspectives 
The present work has identified a number of areas for further investigation. 
4.6.1 Biomarker development  
4.6.1.1 Development of high through put measurement of HBPs 
 
Immunoassays are the gold standard to measure protein/peptide targets due to 
their high sensitivity, high throughput and cost-effectiveness (Lequin, 2005). 
However, the development of these for new targets is expensive and would be 
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an unattractive proposition for candidate evaluation in which a high attrition 
rate may be anticipated. Multiple reaction monitoring (MRM) is an emerging MS 
high throughput approach and uses specific peptides as surrogates of proteins 
(Huttenhain et al., 2009). The ability of multiplexing with MS enables the rapid 
and cost-effective evaluation of a large list of candidate biomarkers and may 
facilitate the development of personalized medicine strategies in treating 
disease (Percy et al., 2014).  
 
4.6.1.2 Serum biomarker development 
Identification of putative candidates in clinical samples is an important first step 
in biomarker development. Serum or plasma is routinely analyzed in the clinical 
laboratory for biomarkers. However, these are the most challenging samples to 
analyze by proteomic techniques, as serum has a wide dynamic range of protein 
concentrations (Anderson and Anderson, 2002). This wide dynamic range 
allows for identification of high and medium abundance proteins, while low 
abundance proteins are often overlooked. Modification of sample preparation 
with enrichment techniques such as affinity chromatography to isolate the 
heparin-bound fraction may help reduce the sample complexity and obviate this 
problem in the case of HBPs. 
 
4.6.1.3 Validation of potential biomarkers  
Validation has to be done to make sure the putative biomarkers are specifically 
associated with AP. Before these biomarkers can be developed into useful 
clinical assays, they have to be validated and their sensitivity and specificity 
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needs to be established. Samples should be obtained not only from AP patients 
and healthy donors, but also from patients who have similar diseases and a 
broad range of individuals within the population. This requires a very large 
number of appropriately collected and documented clinical samples. The NIHR 
Liverpool Pancreas Biomedical Unit AP biobank stores high quality samples 
from patients with AP and healthy volunteers. It is ethically approved and 
functions within HTA, GCP (Good Clinical Practice) and GCLP (Good Clinical 
Laboratory Guidelines) and so would provide the source of material for such 
further studies.  
The data presented in this thesis indicated that the proteins in Table 3.5.1 are 
the most likely candidates for the identification of biomarkers. This is based on 
their relative expression in AP versus NP and on the knowledge that these are 
secreted proteins, rather than membrane- or matrix-associated. 
 
 
4.6.2 Drug development 
As noted in Section 3.5.6, the protoemics analysis has identified a number of 
HBPs that are more highly expressed in AP for which there are existing drugs, 
either approved or undergoing clinical trials for other diseases.  Thus, 
repurposing trials in AP may lead to improved patient outcome.  
There is the possibility of a very different approach, which draws inspiration 
from regenerative medicine strategies of some Glycotech companies. These 
have targeted HBPs using chemically modified heparins and heparin mimetic 
polymers. For example, Regenerative agent (RGTA) is a carboxymethylated 
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dextran that is statistically sulfated, which is used for ocular and dermal wound 
healing (the latter includes lower limb ulcers of diabetics) to treat lower limb 
ulcers of diabetics with some success. These polymers do not have a mechanism 
mode of action, and this may underlie their efficacy: they target multiple HBPs 
and so may be able to reduce, for example, the activity of DAMPs while 
promoting the activity of HBPs that drive tissue regeneration.  The definition of 
the statistical substitution that is clinically effective has hitherto been empirical; 
their application in a trial in AP similarly has to determine which range of 
sulfation is effective.  However, the further development of the systems analysis 
of HBPs in this thesis alongside a structural analysis of the heparin binding 
motifs using high throughput methods such as differential scanning fluorimetry 
(Uniewicz et al., 2010, Xu et al., 2012) may provide a means to define prior to 
embarking on a trail the likely sulfation substitution of these polymers that will 
be effective.  
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